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 Medulloblastoma is the most common malignant brain tumor in children.  Group 
3 medulloblastoma is associated with high expression of the MYC oncogene and has the 
worst clinical prognosis.   To investigate the biology of these tumors and develop new 
therapeutic strategies, we transduced human neural stem and progenitor cells derived 
from the cerebellar anlage with key oncogenic driver elements associated with aggressive 
medulloblastoma.  Cells transformed with MYC, dominant-negative TP53, constitutively 
active AKT and hTERT formed brain tumors that histologically, pathologically, and 
genetically resembled the Group 3 subtype of medulloblastoma. Median survival of these 
tumor-bearing animals was 117 days.  To facilitate rapid screening of a large number of 
available drugs, we applied a new in silico analysis technique named DiSCoVER 
(Disease-model Signature vs. Compound-Variety Enriched Response) that used the 
expression profile of the human neural stem cell model and existing drug sensitivity 
databases to identify novel therapeutic targets.  The DiSCoVER analysis predicted MYC-
expressing Group 3 medulloblastoma would be sensitive to cyclin-dependent kinase 
(CDK) inhibitors.  We confirmed activity of the CDK4/6 inhibitors palbociclib and 
flavopiridol in MYC-expressing medulloblastoma. Specifically, palbociclib decreased 
proliferation of our human neural stem cell model and medulloblastoma cell lines by an 
average of 62% (p<0.01) and increased the percentage of apoptotic cells by an average of 
150% (p< 0.04). Palbociclib treatment extended the median survival of mice with 
orthotopic MYC-driven medulloblastoma xenografts by 48% (p=0.003).   MYC is known 
to regulate glutamine metabolism, and we also used our neural stem cell model to 
investigate the hypothesis that MYC-driven medulloblastoma would be sensitive to 
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inhibition of glutamine metabolism.   Treatment with the glutamine analogs Acivicin or 
6-diazo-5-oxo-l-norleucine (DON) significantly increased the percentage of apoptotic 
cells by an average of 290% (p<0.04) and 164% (p<0.04), respectively.  DON therapy 
increased the median survival of mice with MYC-driven orthotopic medulloblastoma 
xenografts by up to 246% (p=0.0018).   In summary, this dissertation presents a novel, 
genetically accurate human neural stem cell model of aggressive medulloblastoma, and 
provides preclinical evidence for the use of CDK inhibitors and glutamine analogs in 
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PART I:  DEVELOPMENT OF A HUMAN NUERAL STEM CELL MODEL OF 
MEDULLOBLSTOMA AND THE IN SILICO DRUG SCREENING TECHNIQUE 
DISCOVER 
 
CHAPTER 1: INTRODUCTION TO MEDULLOBLASTOMA  
1.1 Medulloblastoma Overview 
The cerebellar tumor medulloblastoma is the most common malignant pediatric 
brain tumor (1).  Children typically present with symptoms related to increased 
intracranial pressure and cerebellar dysfunction.  Headache, nausea (especially upon 
waking), dizziness and ataxia are common (2).  Standard treatment consists of surgical 
resection, radiation and chemotherapy.   Around 60% of medulloblastoma patients 
survive for at least 10 years (3). Treatment is associated with high morbidity; 
medulloblastoma patients often experience cognitive delays and learning disabilities, 
leading to difficulties in school and social problems.  Hearing loss, a side-effect of high-
dose chemotherapy and radiation, can also contribute to educational difficulties. (4, 5)  
Around 25% of medulloblastoma patients will experience cerebellar mutism following 
surgical resection, a condition associated with ataxia, poor coordination, and irritability in 
addition to absent speech that can persist from weeks to years (6).  Surviving patients are 
also at increased risk for stroke (4, 7), endocrine problems (8), and development of 
secondary neoplasms (9). The significant morbidity associated with medulloblastoma 
indicates a need for better therapies.   
Around two-thirds of medulloblastoma patients will survive long-term, but this 
seemingly good survival rate hides the complexity of this disease.  Some patients will 
respond well to therapy and experience tumor remission without recurrence, while others 
will experience tumor metastasis, recurrence and the development of therapeutic 
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resistance and ultimately die from their disease (1).  Historically, medulloblastoma was 
classified based on histologic characteristics.  Patients with a desmoplastic/nodular 
histology were categorized as having good outcomes. Tumors with “classic” histology 
were considered standard risk, and large/cell anaplastic tumors generally having poor 
outcomes. Patients with metastatic disease or significant post-operative residual tumor 
also tended to have poorer outcomes. (10)  Genetically, MYC expression is known to 
correlate with anaplasia and poor outcome (11-14).   
 
1.2 Medulloblastoma Molecular Genetics 
Recently RNA expression profiling and DNA methylation studies have 
subdivided medulloblastoma into four molecular subgroups:  WNT, SHH, Group 3, and 
Group 4 (15, 16).    These four subgroups vary in their clinical prognoses and molecular 
genetics.   Some researchers, such as Cho et al (14), identify six molecular subgroups, C1 
through C6 (hereafter referred to as the Cho subgroups), which can be nested into the 
four consensus subgroups.  In addition to differing prognoses and genetics, certain 
subtypes are also more common in certain age groups, perhaps reflecting a difference in 
cell-of-origin between the groups.  
The WNT subgroup (Cho subgroup C6) represents 10% of medulloblastoma 
tumors (10, 14, 17).  This subgroup is characterized by dysregulation of the WNT 
signaling pathway, most frequently caused by mutations in β-catenin (CTNNB1), and loss 
of one copy of chromosome 6 (15, 16). Most children diagnosed with WNT tumors are 
school-aged (15).  Patients with WNT-group tumors respond well to therapy and have 
95% 5-year survival rate (10).  Phoenix et al proposed that WNT driven medulloblastoma 
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is essentially curable because the mutant β-catenin signaling leads to the development a 
particularly permeable blood-brain barrier within the tumor and its surrounding 
environment allowing high-levels of chemotherapy to accumulate within the tumor (18).  
SHH tumors (the other tumor type studied by Phoenix et al) have a more intact blood-
brain barrier, allowing lower levels of chemotherapy to accumulate (18). These WNT-
tumor patients do so well, it is thought their disease might respond to less therapy than 
the current standard of care.  An open clinical trial is currently testing the efficacy of 
surgery and chemotherapy without radiation for patients with WNT-positive 
medulloblastoma tumors (Trial Number: NCT02212574).  
  Around 30% of medulloblastoma patients have SHH-type tumors (Cho subgroup 
C3) (10, 14, 17) .  This subgroup is characterized by mutations in the SHH pathway (15).  
Mutations are found at multiple points in the pathway, including GLI2, PTCH and SUFU 
(17, 19).   PTCH mutations can be inherited, resulting in Gorlin Syndrome.  Gorlin 
patients are predisposed to multiple types of cancer, including medulloblastoma (17).  A 
subset of SHH patients have mutations in TP53 (19).  Like PTCH mutations, TP53 
mutations can be inherited causing the cancer pre-disposing Li-Fraumeni Syndrome.  Li-
Fraumeni patients are pre-disposed to developing medulloblastoma in addition to other 
cancer types. (19)  Clinical prognosis varies within the SHH group.  Patients with TP53 
mutant tumors tend to do very poorly, while patients without TP53 and/or GLI2 
mutations have a better clinical outcome (20).   Infants, older adolescents, and adults 
diagnosed with medulloblastoma typically have SHH group tumors (15).    
 Group 3 and Group 4 tumors are less well characterized than SHH and WNT 
tumors.  These tumor types most commonly occur in school-aged children (15). Group 3 
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(Cho subgroups C1 and C5) is the most clinically devastating of the subgroups and 
comprises about 25% of medulloblastoma tumors (10, 14).  Group 3 tumors are most 
commonly associated with amplification or over-expression of the MYC oncogene (10, 
17).   MYC overexpression is associated with anaplastic histology—traditionally a sign of 
poor prognosis (11).  These MYC-amplified medulloblastoma tumors make up Cho 
subgroup C1, with the non-MYC amplified Group 3 tumors falling into Cho subgroup C5 
(14).  In many cases, the increased levels of MYC mRNA are associated with DNA 
amplicons at this locus (13, 21), but in other tumors the precise cause of MYC 
upregulation is unclear. Several groups have previously shown that increased MYC 
expression can promote medulloblastoma formation, growth and an anaplastic tumor 
phenotype (11, 22, 23).  Ultimately, only around 50% of patients with a Group 3 tumor 
survive long term.  About 35 to 40% of these tumors will metastasize to the 
leptomeningeal space and/or spine. (24)  Group 4 tumors (Cho subgroups C2 and C4) 
comprise about 45% of medulloblastoma tumors (14, 24).  In this subgroup, mutations 
are often found in NMYC, CDK6, and SNCAIP (19).  Around 75% of patients with a 
Group 4 medulloblastoma tumor will survive long-term.  About 40 to 45% of Group 4 
tumors ultimately metastasize (24).   
 Medulloblastoma probably arises from immature embryonal cells in the 
cerebellum.  The developing cerebellum has multiple distinct progenitor cell populations, 
and research suggests that the distinct molecular subgroups of medulloblastoma arise 
from these different progenitor populations.  WNT medulloblastoma is thought to arise 
from neural progenitor cells of the dorsal brain stem, while SHH tumors are thought to 
arise from the cerebellar granule neural progenitors (CGNPs) of the external granule 
5 
 
layer (EGL) and rhombic lib. (24-26) There is less evidence for the cells of origin for 
Group 3 and Group 4 tumors.  Group 3 tumors may arise from the CGNPs of the EGL or 
the neural progenitors of the ventricular zone in the fourth ventricle. (24)  Recent work by 
Lin et al suggests that the cells of origin for Group 4 medulloblastoma are found in the 
deep cerebellar nuclei (DCN) of the nuclear transitory zone or possibly DCN progenitors 
in the upper rhombic lip. (27) 
 
1.3 Medulloblastoma Models 
1.3a Cell Culture Models 
 A variety of tools, each with advantages and drawbacks, exist to study 
medulloblastoma in the laboratory.   There are 44 well established, patient-derived cell 
lines that have been in continuous use/culture over the past several decades (28).  
According to a 2016 review, efforts in genetic analysis have sorted less than half (18/44) 
of these cell lines into the four consensus subgroups, with varying degrees of certainty 
(28).  Of the subgrouped cell-lines, around 60% (11/18) fall into Group 3 due to 
amplifications in MYC.  About 20% (4/18) are classified as SHH tumors, with half of 
those having TP53 mutations.  Two cell lines are considered Group 4 (both derived from 
the same patient), and only one has been classified as WNT. (28)  A subset of these cell 
lines will form tumors when implanted into immune-deficient mice.  The long-term use 
of some of these cell lines makes them are useful in vitro tools because current results 
and experiments can be compared to past work.  However, there are many drawbacks to 
using cells that have been cultured for long periods of time.  Genetic drift over time is a 
very legitimate concern.  As cells adapt to culture conditions, their original genetic 
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alterations may be lost, or new genetic mutations acquired (29).  Additionally, the 
original patient tissue from which the cell line was derived is often currently unavailable, 
as many of these cell lines were established decades ago.   The accuracy of these long-
term cell culture models must be considered when they are used for studies.  
 Primary, short-term medulloblastoma models can also be used as a model system, 
albeit with more technical difficulties than long-term culture models.   Primary cultures 
are probably more genetically representative of primary tumors, and the tissue of origin is 
often available for analysis or comparison.  These cultures are also more heterogeneous, 
containing multiple cell types from the primary sample, not just tumor cells.   Primary 
culture models can only be considered such for a few passages, making them only 
useable as a “primary” model for the short term.   
1.3b Serially Passaged Xenograft Models 
 In addition to creating primary cell lines in vitro, primary patient samples can be 
immediately injected into the brains or flanks of immune compromised mice.   If a tumor 
forms, it can be passaged into additional animals, creating a patient-derived xenograft 
model.  These models are viewed as being more accurate than in vitro cell-culture 
systems because the tumor is growing in conditions more similar to a human brain and 
there are not the selective pressures faced by a sample being forced to adapt to culture 
conditions.  Rough 20 serially passaged xenograft medulloblastoma cell lines are 
available for purchase from the Brain Tumor Resource Laboratory run by Jim Olson at 
the Fred Hutchinson Cancer Research Center (btrl.org).  These lines have been 
characterized by medulloblastoma subgroup.  However, a mouse brain is not a human 
7 
 
brain, and serially passaged xenografts have been shown to experience changes in gene 
expression as they are passaged (30).    
1.3c Mouse Models  
 In addition to xenografting, several genetically engineered mouse models 
(GEMM) of medulloblastoma exist. Around 15% of mice heterozygous for Ptc (the 
mouse equivalent of PTCH) expression will spontaneously develop a medulloblastoma-
like tumor (31).  When Ptc heterozygosity is combined with Trp53 (the mouse gene 
coding for p53) heterozygosity, the incidence of tumor formation increases to 95% (32).  
Ptc heterozygosity combined with various other genetic deficits (including deficiency of 
Kip1 and Ink4c) also will result in formation of medulloblastoma tumors (33, 34).   Initial 
mouse models featured mice with global Ptch heterozygosity.   Using Cre-lox 
technology, Ptc can be specifically knocked-out post-natally in granular neural precursor 
(GNP) cells of the cerebellum resulting in fully penetrant medulloblastoma formation 
(35).  Mice with mutations in the SHH signaling pathway other than Ptch (Sufu and Smo) 
have also been generated.   In total, around 17 different GEMM-models of SHH-
medulloblastoma have been created. (36)    
Few GEMMs exist for the other subgroups of medulloblastoma.  Expressing 
mutant Ctnnb1 in the cells of the cerebellar ventricular zone and the lower rhombic lip is 
not sufficient to induce tumor formation, but when Tp53 expression is also knocked out, 
WNT-like tumors form in around 15% of mice (25).  Swartling et al created a non-SHH, 
non-WNT GEMM model of medulloblastoma (called the GTML model) by inducing 
MYCN expression in cells expressing GLT1 (glutamate transporter) (37).   Unlike the 
majority of other mouse models of medulloblastoma, the GTML model forms metastases 
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(36, 37). The majority of medulloblastoma patients die of metastases and recurrent 
disease, so there is a critical need to study the biology of medulloblastoma metastasis to 
develop better therapeutics (36).  
 There are also multiple non-genetically engineered mouse models of 
medulloblastoma.  If Shh-expressing retrovirus is injected into the cerebella of embryonic 
mice in utero, around three-quarters of the injected animals will develop 
medulloblastoma after birth (38).  The RCAS/tv-a system can also be used to induce 
medulloblastoma formation.   In this system, RCAS vectors carrying genes of interest 
were transfected into DF-1 cells, which are then injected into the cerebella of mice that 
expressed TV-A under the control of the Nestin promoter, thus causing TV-A to be 
expressed in neural progenitor cells.  Using this system, it was shown that both Myc and 
MycN and Igf2 can combine with Ptc heterozygosity to promote medulloblastoma 
formation. (39-41).   
 Two separate groups created models of Group 3 medulloblastoma by implanting 
previously isolated and transfected mouse neural stem cells into the cerebella of mice.  
Kawauchi et al transfected granular neural precursor cells isolated from the cerebella of 
postnatal day 6 Trp53 null mice with Myc.  These implanted cells formed tumors that 
killed mice in a median of 39 days.  Genetic analysis indicated that these tumors highly 
expressed the mouse orthologues of the genes that characterize human Group 3 
medulloblastoma tumors (23).  Pei et al isolated cells from the cerebella of C57BL/6J 
mice on the basis of Promin1 (CD133) expression and the lack of expression of neuronal 
and glial markers.  These cells were transfected with Myc and dominant-negative Trp53 
retrovirus and transplanted into the cerebella of nude mice.  The resulting tumors were 
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histologically similar to primary Group 3 tumors and reduced the survival of implanted 
mice to a median of 49 days.  Genetic analysis showed these tumors and human Group 3 
tumors have similar gene expression profiles. (22)   
Modeling medulloblastoma in mice has led to great advances in our understanding 
of the cell of origin and other biological features of the various molecular subtypes.  
However, questions can arise when performing cross species comparisons. Murine cells 
are not always transformed in a fashion equivalent to human ones (42, 43), and 
expression profiles can be challenging to reconcile between mouse and human. For 
example, it has been suggested that the MYCN driven murine model may represent a 
better molecular match for human Group 3 tumors than MYC driven ones, despite the 
fact that MYCN is most prominent in other medulloblastoma subgroups (44).   Thus one 
of the goals of this dissertation is to show the creation of a human model of MYC-driven 
medulloblastoma using neurospheres derived from the developing human cerebellum and 
to use these transformed cells to interrogate new treatments.  A human neural stem cell 
model of medulloblastoma that faithfully recapitulates the overall oncogenic state of 
these tumors can be a powerful tool.   An additional motivation for this strategy is the fact 
that medulloblastoma tumors are genetically relatively simple, having 5 to 10-fold fewer 







CHAPTER 2:  RESULTS  
2.1 Group 3 primary medulloblastoma tumors express MYC, phospho-AKT, and 
TP53  
To generate a genetically defined model of aggressive medulloblastoma, we 
began with human neural stem and progenitor cells obtained as described in (46) (Figure 
1 A,B).  These cells express the stem cell marker CD133 and the neural stem cell markers 
NESTIN, SOX2, and GFAP (Figure 1C).  We used a tissue microarray (TMA) containing 
65 primary human medulloblastoma samples that was previously characterized with 
respect to subgroup (15) to interrogate the expression of oncogenic elements associated 
with Group 3/C1 medulloblastoma. Group 3 tumors are known to overexpress MYC at the 
mRNA level (12), but MYC protein expression has not been extensively investigated in 
primary tumors. Immunohistochemical analysis of MYC on our TMA showed that 
expression was highest in Group 3 tumors (Figure 1D), with 50% expressing MYC, while 
only 27% of SHH tumors and 6% of Group 4 tumors had detectable MYC protein levels.  
In addition to MYC, Group 3 samples had significantly higher expression of TP53 
(Figure 1E), indicating dysfunction of the p53 pathway.  Among Group 3 tumors, 56% 
were positive for increased TP53 expression, while only 25% of SHH tumors and 23% of 
Group 4 tumors were positive for TP53. Our group has demonstrated that anaplastic 
medulloblastoma tumors have elevated TP53 expression (47, 48), suggesting inactivation 
of the p53 pathway. We and others have shown that increased TP53 protein levels or 
TP53 mutations are associated with worse clinical outcomes in a subgroup-dependent 
fashion (20).  
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We next investigated the expression of phospho-AKT as an indicator of mTOR 
status. The mTOR pathway is active in multiple medulloblastoma subgroups, including 
Group 3 and is associated with increased metastasis (49).   We identified increased 
phospho-AKT staining in all subgroups represented in our TMA.  Although there was a 
trend for increased AKT signaling in Group 3, it did not reach statistical significance 
(Figure 1F).  In addition to MYC, TP53 and phospho-AKT, human telomerase (hTERT) 
has been identified as being highly expressed in embryonal tumors, and was included as a 
transforming element (50, 51).   
 
2.2 Neural stem cells transduced with MYC, dominant-negative TP53, hTERT, and 
AKT form aggressive tumors that phenocopy Group 3 medulloblastoma  
The addition of MYC alone or with AKT, DNp53 and hTERT increases 
proliferation compared to normal neural stem cells and to cells immortalized with SV40 
(Figure 2A). The human MYC transformed cells were ATOH negative (data not shown), 
consistent with prior murine models of MYC-driven medulloblastoma (22). Cerebellar 
derived neural stem and progenitor cells transduced with dominant-negative TP53, MYC, 
constitutively active (myristolated) AKT, and human telomerase (hTERT) formed 
aggressive tumors when injected into the brains of nude mice (Figure 2B).   Cerebellar 
stem cells immortalized with SV40 did not form tumors (Figure 1B).   
The tumors expressed TP53, MYC, and phospho-AKT, indicating that these 
oncogenic elements used to drive transformation were maintained (Figure 2C).  Tumors 
formed by cells transduced with all four oncogenic elements also had anaplastic features 
(Figure 2D i) and could spread to the leptomeningeal space (Figure 2D ii).  
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Approximately 20% of mice had spinal metastases (Figure 2D iii).  Metastasis is 
associated with Groups 3 and 4, the most aggressive subgroups of medulloblastoma (52).  
The DN-TP53 hTERT AKT MYC orthotopic xenografts expressed NESTIN and MAP2 
and were negative for GFAP (Figure 2E), indicating a primarily progenitor and neuronal 
phenotype consistent with medulloblastoma.    Because no effective antibody exists for 
hTERT immunohistochemistry, we verified high-level expression of this hallmark in our 
4-gene transduced cells by qPCR (data not shown).   
 
2.3 Human neural stem cell models of Group 3 medulloblastoma share mRNA 
expression profile with human primary tumors  
To further confirm that our model replicates Group 3 medulloblastoma, we 
performed Affymetrix mRNA expression profiling on our human cerebellar neural stem 
and progenitor cell models and two of our DN-TP53 hTERT AKT MYC tumor 
orthotopic xenografts.  Specifically, we examined the expression of 32 pathways that 
have been previously associated with each of the six Cho subgroups (53).  High 
expression of a specific subset of each of these 32 pathways is characteristic of each 
subgroup. We performed single-sample gene-set enrichment analysis (ssGSEA) on our 
model in culture and as xenografts to obtain an enrichment score for each of the 
medulloblastoma associated pathways.  This analysis was also performed for the primary 
medulloblastoma tumor dataset of Tamayo et al. 2011 (53), allowing us to compare the 
profiles of our xenografts and cultured cells against human medulloblastoma tumors.  The 
pathway enrichment profile of our cells and xenografts closely matches the profile of C1 
primary tumors, the most aggressive subclass of patients within MYC-driven Group 3 
(14) (Figure 3A, green boxes). Samples from cells transduced with only MYC expressed 
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the Group 3 associated mRNAs and corresponding pathway enrichment.  The addition of 
DN-TP53, hTERT and AKT to MYC increased the expression of these Group 3 
associated pathways.  The orthotopic xenografts of cells transduced with MYC, DN-
TP53, hTERT and AKT most highly express the Group 3 associated mRNAs. (Figure 3B)    
We also generated an association matrix that compares the pathway enrichment 
scores of xenografts and cell models against each tumor subtype (Fig. 3C). The 
association is estimated using the Information Coefficient, an information-theoretical 
counterpart to the correlation coefficient (see Chapter 4.7 for details). Primary cultures of 
untransduced cerebellar neural stem and progenitor cells associate most closely with the 
C6/Wnt subgroup.  The sequential addition of MYC, TP53, hTERT and AKT increases 
the association with the C1 subtype. Growth of these cells as orthotopic xenograft tumors 
further increases the association with the subtype C1 (Fig 3C).      
 
2.4 Analysis of drug sensitivity databases with a profile created by analyzing the 
human neural stem cell model of Group 3 medulloblastoma reveals CDK inhibitors 
as a potential therapeutic target 
The human neural stem cell model of medulloblastoma was used as a test subject 
for a novel computational analysis technique, DiSCoVER (Disease-model Signature vs. 
Compound-Variety Enriched Response), that we briefly describe here (see Chapter 4.6 
for details).  We created a gene set called the “hNSC G3 signature” of the 150 most up-
regulated genes in the murine xerographs of human neural stem cell line transformed 
with DNp53, hTERT, constitutively active AKT and MYC (Table 1).We then analyzed 
the gene expression datasets of two mRNA datasets using single-sample gene set 
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enrichment analysis (ssGSEA).   This analysis allowed us to obtain a hNSC G3 signature 
enrichment score for each sample in the two mRNA datasets.  We then matched the 
signature enrichment scores against drug sensitivity profiles that have been generated for 
the same samples. In this way, we identified compounds that killed cells sharing a high 
hNSC G3 enrichment score. We performed this comparison against three different drug 
sensitivity datasets and looked for overlaps in the top scoring compounds or their 
compound varieties.  A summary of the procedure is shown in Figure 4A. 
In this analysis we focused on the top scoring compounds with False Discovery 
Rates (FDR) below 0.33.  The overlap analysis across datasets revealed that cancer cell 
lines that highly express the hNSC G3 signature are sensitive to the cyclin-dependent 
kinase inhibitors (Figure 4B). These inhibitors include the pan-CDK inhibitor 
Flavopiridol/Alvocidib (PubChem CID: 5287969) (54), CDK 1/2/5/7 inhibitor CGP-
60474 that was developed as a PKC inhibitor (PubChem ID: 644215) (55), CDK4 
inhibitor CGP-082996 (PubChem CID: 24825971), and the CDK4/6 inhibitor PD-
0332991/Palbociclib (PubChem ID: 5330286) (56). MYC expression is known to 
increase the expression of cyclin-dependent kinases, so CDK inhibition is biologically 
congruent with the in silico screen (57).   
 
2.5 The CDK4/6 inhibitor palbociclib and the pan-CDK inhibitor flavopiridol 
decrease proliferation in the human neural stem cell model of medulloblastoma and 
patient-derived medulloblastoma cell lines  
Of the CDK inhibitors identified by the DiSCoVER analysis, we decided to test 
palbociclib (PD-0223991) because of its clinical relevance.  Palbociclib is used clinically 
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for the treatment of recurrent breast cancer.  In addition to cerebellar neural stem cells 
transformed with MYC, DNp53, AKT and hTERT, we used cerebellar neural stem cells 
transformed with MYC alone and two MYC-expressing, patient-derived 
medulloblastoma lines (D425Med and D283Med) to test the effects of palbociclib on 
medulloblastoma.  Inhibition of CDK4/6 activity prevents the phosphorylation of the 
retinoblastoma protein (Rb) (56).  Western blotting showed that 5uM palbociclib 
treatment led to a decrease in phosphorylation of Rb at two different phosphorylation 
sites (Ser780, and Ser807/811) in all medulloblastoma cell lines test.  Phosphorylation at 
S780 decreased by 96% in cells transformed with MYC alone, by 62% in cells 
transformed with all four oncogenes, by 24% in D425Med cells, and by 37% in 
D283Med cells.  The phosphorylation at S807/811 decreased by 99% in MYC alone 
cells, 56% in cells transformed with all four oncogenes, by 33% in D425Med cells and 
by 43% in D283Med cells. (Figure 5A).   Neural stem cells immortalized with SV40 
were not tested because SV40 functions through suppression of Rb (58).   
Palbociclib treatment caused a significant decrease in proliferation in all four 
medulloblastoma models, as determined by BrdU incorporation (Figure 5B).  5uM 
Palbociclib treatment for 72h caused the percentage of BrdU positive cells to decrease 
from 41% to 3% in cells transformed with MYC alone (p=0.0000009 by Student’s t-test), 
from 30% to 13% in cells transformed with all four oncogenic elements (p=0.02 by 
Student’s t-test), from 32% to 12% in D425Med (p=0.000004 by Student’s t-test), and 
from 40% to 21% in D283Med (p=0.004 by Student’ t-test).  In cells immortalized with 
SV40, palbociclib caused a modest decrease in BrdU incorporation—34% BrdU positive 
cells to 24% (p=0.06 by Student’s t-test) (Figure 5B). The pan-CDK inhibitor 
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flavopiridol, which was also identified by DiSCoVER, decreased the percentage of BrdU 
positive cells from 62% to 17% in neural stem cells only transformed with MYC 
(p=0.000014 by Student’s t-test), from 27% to 14% in cells transformed with all four 
oncogenes (p=0.00055, by Student’s t-test), from 51% to 35% in D425Med cells (p=0.03, 
by Student’s T-test) and from 47% to 29% in D283Med cells (p=0.000008, by Student’s 
T-test) (Figure 6A). 
 
2.6 Palbociclib and flavopiridol induce apoptosis in human MYC-driven 
medulloblastoma cells 
Palbociclib treatment increased apoptosis in medulloblastoma models that express 
MYC (Figures 5C and 5D).  Treatment with 1uM or 5uM of palbociclib for 24h caused 
an increase in the expression of cleaved-PARP (as measured by Western blotting), 
indicating increased levels of apoptosis (Figure 5C).  Treatment of our MYC-driven 
human neural stem cell models of medulloblastoma with 5uM of palbociclib for 72h 
caused the percentage of cleaved caspase-3 positive cells in to increase from 20% to 70% 
in cells immortalized with MYC alone (p=0.0000004 Student’s t-test), from 21% to 45% 
in cells transformed with all four oncogenic elements (p=0.000002 by Student’s t-test), 
from 7% to 21% in D425Med (p=0.0005 Student’s t-test),  and from 3% to 9% in 
D283Med (p=0.001 Student’s t-test) (Figure 5D).  In SV40 immortalized cells, 5uM 
palbociclib caused a modest increase in the percentage of cleaved-caspase 3 positive 
cells—10% to 15%--but this was not statistically significant (p=0.14 by Student’s t-test) 
(Figure 5D).  
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 Like palbociclib, flavopiridol also caused an increase in apoptosis as measured 
by cleaved caspase-3 immunofluorescence (Figure 6B).  Treatment with 100nM of 
flavopiridol increased the percentage of cleaved caspase-3 positive cells from 4% to 62% 
in human neural stem cells transformed with MYC alone (p=0.00008 by Student’s t-test), 
from 5% to 31% in cells transformed with all four oncogenic elements (p=0.000001 by 
Student’s t-test), from 6% to 23% in D425Med cells (p=0.4 by Student’s t-test), and from 
2% to 12% in D283Med cells (p=0.02 by Student’s test).    In SV40 immortalized cells, 
flavopiridol treatment caused a modest increase in cleaved caspase-3 positive cells—1% 
to 4%-- and though this change was statistically significant (p=0.005 by Student’s t-test) 
it is unlikely to be biologically meaningful (Figure 6B). 
 
2.7 Palbociclib significantly improves survival of mice with medulloblastoma 
orthotopic xenografts 
  We next tested the efficacy of palbociclib as a monotherapy in vivo.  Palbociclib 
treatment has been shown to increase survival in a mouse models of brainstem glioma 
and GBM (59, 60). Palbociclib treatment significantly extended survival of nude mice 
with D425Med intracranial xenografts by 48%--from 25 to 37 days (p=0.003 by Log-
rank test) (Figure 7A).  Palbociclib treatment significantly extended the survival of nude 
mice with DNp53 hT AKT MYC tumors by 22%--from 162 to 197 days (p=0.0322 by 
Log-rank test).  To verify that palbociclib was causing this effect by inhibiting CDK 
function, we performed IHC for phospho-Rb on D425Med tumors from animals that 
were given a single dose of vehicle or palbociclib four hours prior to euthanasia.  Tumors 
from mice given palbociclib had a significantly lower percentage of phospho-Rb positive 
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cells compared to mice given the vehicle control (38% vs 54%, p=0.00025 by Student’s t-
test), indicating that the drug cross the blood brain barrier and penetrates the tumor 
(Figure 7C).   Images of two tumors from mice given vehicle are in Figure 7D, left. 
Images of two tumors from mice given palbociclib are in Figure 7D, right.   We were 
















CHAPTER 3:  DISCUSSION  
Group 3 medulloblastoma is a highly lethal disease. The human neural stem and 
progenitor cell model presented here phenotypically, histologically and genetically 
mimics the C1 component of Group 3, the most lethal sub-group of medulloblastoma (14, 
53). Although our model shares MYC activation and p53 pathway inhibition with the 
murine neural stem cell models created by Pei et al (22) and Kawauchi et al (23), the 
addition of activated AKT, which is a known driver of medulloblastoma metastasis and 
resistance to therapy as well as hTERT, which reflects the high frequency of TERT 
promoter mutations in medulloblastoma, adds a richness to our model (50, 61). The 
increasing fidelity of our human neural stem cells to Group 3 with the sequential addition 
of oncogenic elements as demonstrated in Figure 3 highlights this point.  
Our model might also serve as a model for recurrent and metastatic disease. The 
majority of medulloblastoma patients initially respond to therapy.  Patients that die of 
their disease are dying from relapsed, sometimes metastatic, disease, making recurrence 
and metastatic models critical.   Recurrence patterns vary between the four 
medulloblastoma subgroups;  SHH-type tumors are more likely to reoccur locally, while 
Group 3 and Group 4 tumors are more like to recur as metastases (52).  Medulloblastoma 
tumors retain their subgroup identity when they reoccur, whether or not the recurrence is 
local or metastatic, suggesting that subgroup-affiliation is determined by cell of origin 
(52).    Though subgroup affiliation remains stable, there are genetic changes at 
recurrence.  Hill et al found that alterations in MYC and the TP53 pathway often occur 
together in relapsed medulloblastoma of all subtypes (62).   These MYC-TP53 altered 
recurrent tumors were particularly aggressive, with all patients studied in this group 
rapidly succumbing to their disease (62).   Our model expresses high levels of MYC and 
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alterations in the TP53 pathway, through dominant-negative TP53, and so it could serve 
as a model of relapsed disease.  
This dissertation also presents a novel method for in silico prediction of drug 
sensitivity, which we believe may significantly accelerate the identification of novel 
therapeutics for rare cancer types. Our DiSCoVER approach differs from existing in 
silico methods such as Connectivity MAP (C-MAP) in that DiSCoVER uses the actual 
drug response cell viability profiles (e.g. IC50 or AUC) of multiple drug screening 
datasets involving hundreds of cell lines treated with each drug, rather than the 
transcriptional changes, such as those detected by 1,000 “landmark” genes, induced by 
drug perturbations in a few selected cell lines as it is done in CMAP. The drug screening 
responses are more accurate at representing the effect of a drug in terms of affecting cell 
viability and not only transcriptional changes that may, or may not, impinge on cell 
viability. 
CMAP matches the gene set representing the disease signature against 
transcriptional profiles of drug perturbations in a few cell lines using the Kolmogorov-
Smirnov enrichment statistic. This is a useful approach in general, but sometimes it does 
not easily allow the detection of more subtle disease vs. drug associations in a broader 
context involving a large number and diversity of cellular states. In DiSCoVER we first 
produced an enrichment score for the disease signature in each cell line (using single-
sample GSEA); and then we match the pattern of these scores across hundreds of cell 
lines, against the drug sensitivity profiles for the same cell lines, using an information-
theoretic metric of association. This approach provides a high degree of sensitivity and 
specificity in finding drug responses that match the disease signature, even when the 
relationship, i) is restricted to a few cell lines representing a relevant but narrowly 
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represented biological state, ii) when this relationship is not strictly linear or, iii) when it 
is very weak. DiSCoVER also repeats the analysis in multiple external datasets and then 
compares the results across them, considering drug classes, and not only individual 
instances as occurs in CMAP.  
An identified therapeutic target in our in silico pre-clinical drug screen was 
cyclin-dependent kinases (CDKs).  MYC plays a significant role in regulating the cell 
cycle through variety of mechanisms (63), including by directly regulating the expression 
of  CDKs, cyclins, and E2F transcription factors (63).  Additionally, MYC induces CDK-
activated kinase (CAK) and phosphatases that lead to hyper-activation of cyclin-CDK 
complexes (63).  MYC also antagonizes the activity of cell cycle inhibitors like p21 and 
p27 (63).   MYC-driven murine lymphoma and hepatoblastoma are sensitive to CDK1/2 
inhibition, further highlighting CDKs as a potential Achilles’ heel in MYC-driven 
malignancies (64, 65). Other groups have demonstrated the use of CDK inhibitors in 
treating brain tumors (59, 60).  Faria et al showed the efficacy of an investigational 
CDK1/5/GSK3b inhibitor, alsterpaullone, in MYC-driven medulloblastoma cell lines, 
though much of the tumor suppressing effect was demonstrated to be mediated through 
mTOR inhibition  (66).   Palbociclib (under the trade-name Ibrance) is a CDK4/6 
inhibitor approved for treatment of advanced estrogen-receptor positive breast cancers 
(67). Phase I clinical trials in pediatric brain tumor patients—including patients with 
medulloblastoma--are currently ongoing (NCT02255461).   The data presented here 
provides strong preclinical support for the use of palbociclib in medulloblastoma patients.  
A study by Whiteway et al showing that palbociclib decreased the growth of high-serum 
medulloblastoma cell lines in vitro (68) also provides preclinical support.  We chose an in 
vivo dose of palbociclib consistent with that given in other pre-clinical models, 150 
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mg/kg (56, 59, 60, 69).  However, the MTD of pediatric patients has yet to be reported 
(NCT02255461).  
Methotrexate and cytarabine were among other top hits revealed by the 
DiSCoVER analysis (Tables 2 to 4). These drugs are currently in use in medulloblastoma 
treatment and are structurally similar to pemetrexed and gemcitabine, which were 
recently identified as being active in medulloblastoma xenografts (70). The identification 
of biologically plausible targets and compounds that are being explored by other 
scientists provides strong validation of our in silico strategy of using the hNSC G3 
signature to probe available datasets of drug sensitivity data.  
Identification of increased apoptosis downstream of palbociclib in our cell lines 
and neural stem cell models differs from the standard response to CDK inhibitors, which 
are largely viewed as cytostatic agents in other cancer types (69, 71-74). As we showed 
in Figure 5A, palbociclib treatment causes decreased phosphorylation of Rb.  
Phosphorylation of Rb releases Rb’s inhibition of E2F transcription factors, allowing 
transcription of genes necessary for cycle progression (75).  De-phosphorylated Rb binds 
to E2F transcription factors, preventing transcription initiation and cell cycle progression 
(75). Several studies showed that as a single agent, palbociclib caused cell-cycle arrest, 
but did not lead to apoptosis (69, 71-74).  However, in combination with cytarabine, 
dexamethasone, and bortezomib, palbociclib enhances cytotoxicity (69, 73, 74).  In our 
model, palbociclib induces apoptosis as a monotherapy, so is possible that we will see 
synergy and enhanced cell killing when it is used in combination with other cytotoxic 
agents commonly used to treat in MYC-driven medulloblastoma.  
Among the other candidate drugs in the DiSCoVER prediction, mTOR inhibitors 
occur three times (Tables 2 to 4). mTOR is known to alter cellular metabolism, and 
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Group 3 medulloblastoma showed increased AKT expression compared to normal brain 
(Figure 1). mTOR in specific can activate glutamine metabolism by upregulation of 
glutamine dehydrogenase (GDH). MYC also upregulates glutamine metabolism by 
activating multiple transporters and genes involved in glutaminolysis, including GLS. 
Multiple cancers are thought to have aberrant glutamine metabolism (76-81), and 
inhibiting glutaminase is an attractive therapeutic option in MYC-driven and mTOR-
driven medulloblastoma.  Glutamine metabolism and its role as a potential therapeutic 
target in medulloblastoma will be discussed extensively in Part II. 
This dissertation presents a novel strategy for creating new models of tumors and 
for pre-clinical screening of therapeutic targets.  This strategy enabled us to create a 
human neural stem cell model of Group 3 medulloblastoma and to use this model to 
screen drug sensitivity databases and validate an identified target—palbociclib.   The data 
presented here provides pre-clinical support for the use of palbociclib or other CDK 
inhibitors in carefully selected medulloblastoma patients.  Our overall strategy of using 
tissue-specific human stem and progenitor cells may be useful for developing models of 
other tumor types. The DiSCoVER technique could also be applied to other disease states 







PART II: GLUTAMINE METABOLISM IS A POTENTIAL THERAPEUTIC 
TARGET IN AGGRESSIVE MEDULLOBLASTOMA 
 
CHAPTER 4: INTRODUCTION TO CANCER METABOLISM  
4.1 The Warburg Effect 
It is widely recognized that one of the characteristic “hallmarks” of cancer is 
altered metabolism (82). Interest in the cellular energetics of cancer began early in the 
20th century with Otto Warburg.  Warburg observed that even the presence of oxygen, 
cancer cells performed glycolysis (“aerobic glycolysis”) to produce ATP, rather than the 
more efficient oxidative phosphorylation (83).  Warburg believed that metabolic 
reprogramming to use anaerobic glycolysis to meet energy needs was the fundamental 
cause of cancer (83), and it is now known as the “Warburg Effect.” Modern studies have 
provided support for the Warburg Effect. Positron Emission Tomography (PET) scans of 
human cancer patients show that many tumors take up high levels of glucose.  This 
increase in glucose uptake is sometimes facilitated by upregulation of glucose 
transporters such as GLUT1. (82)  Well known oncogenes (like RAS, AKT, and MYC) are 
involved metabolic reprogramming (84, 85).   
Through a series of ten enzymatic reactions, glycolysis breaks down one molecule 
of glucose into two molecules of pyruvate, generating two molecules of ATP.   In 
differentiated cells under normal oxygen tension, pyruvate is oxidized into acetyl-CoA 
and funneled into the citric acid (TCA) cycle where it is fully oxidized to carbon dioxide 
in a process called oxidative phosphorylation.  Oxidative phosphorylation generates 36 
molecules of ATP.  If differentiated cells are under hypoxic (low oxygen) conditions, the 
pyruvate generated from glycolysis undergoes anaerobic glycolysis (fermentation) to 
generate lactate and two molecules of ATP.   Fermentation allows cells to generate ATP 
25 
 
in low oxygen conditions, but is about 18-fold less efficient than oxidative 
phosphorylation.  
Proliferating normal cells also undergo aerobic glycolysis.  It is somewhat 
counter-intuitive that proliferating cells would perform high levels of aerobic glycolysis 
because it is so much less efficient at generating ATP when compared to oxidative 
phosphorylation (82).   Warburg hypothesized that cancer cells had a deficiency in 
mitochondria, which lead to this dependence on glycolysis for ATP production (86, 87). 
Modern studies have indicated that most cancers do not have mitochondrial deficiencies 
(87, 88) and proliferating normal cells presumably have normal mitochondrial function.  
Differentiated, non-proliferating cells use glycolysis for ATP production in anaerobic 
conditions. Many types of tumors grow hypoxic conditions, perhaps indicating that 
aerobic glycolysis is an adaptation to survive in this environment.  However, cancers that 
grow in locations with abundant access to oxygen (blood cancers and lung cancers) also 
undergo aerobic glycolysis, suggesting that the Warburg effect is not merely an 
adaptation to survive in hypoxic conditions. (84, 87)   
Cell proliferation requires more than the generation of ATP.  Cellular 
proliferation requires large quantities of biomolecules like lipids, proteins and 
nucleotides.  A high rate of biosynthesis requires rapid synthesis of biosynthetic 
precursor molecules. Glycolytic intermediates are a critical source of biosynthetic 
precursor molecules. (85, 87, 89)   The glycolytic intermediate glucose-6-phosphate is 
converted into 5-phosphoribosyl-α-pyrophosphate (PRPP), which is necessary for the 
synthesis of nucleotides.   Glyceraldeyde-3-phosphate, another glycolytic intermediate, is 
converted by cells into glycerol-3-phosphote, a critical intermediate in the generation of 
the phospholipids, sphingolipids, and triacylglycerols that make up the cell membrane.  
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Pyruvate and 3-phosphoglycerate are precursors for the synthesis of the amino acids 
alanine and serine, respectively. (89)  Glycolytic intermediates are crucial for 
biosynthesis, and so it is necessary for a dividing cell to have large pools of these 
intermediates available.  Thus, it is now thought that aerobic glycolysis enables 
proliferating cells to maintain a large supply of the molecules critical for generating the 
biomass necessary for cell division.  (87, 89, 90)   Like glycolysis, the TCA cycle serves 
as a source of biosynthetic intermediates in addition to generating ATP.  Citrate is an 
important substrate for lipid biosynthesis.  Oxaloacetate and α-ketoglutarate are used in 
the synthesis of aspartate and glutamate, respectively.  Aspartate can then be converted to 
asparagine, and proline, arginine and glutamine can be generated from glutamate.  (84, 
89) 
 
4.2 Glutamine Metabolism in Cancer 
 In addition to glucose metabolism, glutamine metabolism is essential to the 
metabolism of both normal cells and cancer cells.  Glutamine is the primary source of 
nitrogen for the synthesis of nucleic acids, other amino acids and hexosamines.   
Glutamine can be metabolized by cells to replenish the intermediates of the TCA cycle in 
a process called anaplerosis.  In the case of anaplerosis, glutamine is being used as a 
carbon source for the synthesis of amino acids and lipids.   Glutamine is converted to 
glutamate by the enzyme glutaminase (GLS).  Glutamate can then be converted to α-
ketoglutarate--a component of the TCA cycle--by glutamate dehydrogenase (GLDH).   
This α-ketoglutarate can be processed through the TCA cycle into oxaloacetate and 
citrate, which are key precursors for amino acid and lipid biosynthesis. (89, 91) This 
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processing of glutamine is sometimes referred to as glutaminolysis (89, 92), and 
replenishment of the TCA cycle by glutaminolysis can generate ATP.   Even when 
glucose—long thought to be the primary source of ATP--is present, glutamine can be 
used to generate ATP.  (89)  For example, glutamine provides 30% of cellular ATP in 
human fibroblasts cultured with glucose (93).   
 Many types of cancers uptake large quantities of glutamine, some to the point of 
becoming “addicted” and being unable to survive without glutamine (77, 78, 81, 94, 95).    
Glutamine addicted cancer cells experience apoptotic cell death following glutamine 
withdrawal, most likely due to decreased anaplerosis (77, 96, 97).   Some cancers might 
depend on a TCA cycle run totally independent of glucose (98).  Zheng et al, however, 
suggest that glutamine-withdrawal-induced apoptosis is related to the depletion of the 
asparagine rather than decreased anaplerosis.  Asparagine is synthesized by the addition 
of a nitrogen from glutamine to aspartate, so decreased cellular access to glutamine 
results in decreased asparagine levels.  In normal situations, depletion of asparagine leads 
to a signaling cascade that increases translation of the ATF4 transcription factor, which 
induces expression of asparagine synthetase (ASNS).   Increased synthesis of asparagine 
then leads to decreased levels of ATF4.  In the case of glutamine withdrawal however, 
ATF4 levels remain high, and ATF4 interacts with CHOP and XBP1 to trigger apoptosis 
(97). 
Cellular utilization of glutamine is largely regulated by the oncogene MYC.  
MYC suppresses the expression of the micro-RNA miR-23a/b which suppresses 
translation of GLS.  High-level expression of MYC effectively “de-represses” GLS and 
leads to increased GLS expression (76).   Expression of the glutamine transporter 
SLC6A14 may also be regulated through miR-23a/b in a similar manner to GLS (99).  
28 
 
MYC directly up-regulates the expression of two additional glutamine transporters: 
SLC1A5 (also known as ASCT2) and SLC7A5 (also known as LAT-1) (78, 99).  
SLC7A5 couples the transport of glutamine and leucine.  Glutamine is transported out of 
the cell and leucine into the cell.  This glutamine-leucine exchange activates additional 
signaling pathways through mTOR (100).  The activities of SLC1A5 and SLC7A5 are 
functionally coupled; the glutamine imported via SLC1A5 is then exchanged for leucine 
by SLC7A5 and mTOR signaling is activated (99).  In both normal cells and cancer, 
signaling through mTOR is critical for cell growth, proliferation and metabolism.  
Dysregulation of mTOR signaling is found in multiple types of cancer, including 
medulloblastoma (101).  Additionally, activation of the mTOR pathway stimulates 
glutamine metabolism by activating GLDH via repression of SIRT4, an inhibitor of GDH 
(102). 
 MYC also regulates the expression of SLC7A11, which exports glutamate and 
imports cysteine for the generation of the anti-oxidant molecule glutathione.  Glutathione 
protects cells against oxidative stress, and in the case of cancer, upregulation of 
SLC7A11 helps prevent apoptosis by increasing glutathione levels, thus reducing 
oxidative damage.  Upregulation of SLC7A11 can facilitate resistance to chemotherapy 
drugs that generate reactive oxygen species. The glutamate exported by SLC7A11 can 
activate glutamate receptors on the surface of cells  (99),  Glutamate receptors regulate 
the proliferation, migration and survival of neurons during brain development, and 
glutamate can act as a growth factor in some cancers, including the malignant adult brain 
tumor GBM (103).   
As discussed in Chapter 1.2, Group 3/C1 medulloblastoma tumors express high 
levels of MYC.   MYC is a potent regulator of glutamine metabolism in other cancer 
29 
 
types, it is logical to hypothesize that Group 3/C1 medulloblastoma tumors will also have 
elevated glutamine metabolism.  The role of glutamine metabolism in medulloblastoma is 
largely under explored, but a study by Wilson et al (104) supports the hypothesis that a 
subset of medulloblastoma tumors have elevated glutamine metabolism.  Wilson et al 
non-invasively measured glutamate levels in the tumors of medulloblastoma patients 
using magnetic resonance spectroscopy (MRS).  They found that patients with high-
levels of glutamate in their tumors had much poorer survival than patients with low 
glutamate levels.  Of the 34 patients in the study, only one had a MYC amplification.  
This patient was in the high glutamate group and only survived for less than two years 
after diagnosis (104).  The initial step in glutamine metabolism is the conversion of 
glutamine to glutamate by GLS.  High levels of glutamate indicate that glutamine is 
being metabolized at a high level.  Thus, Wilson et al’s paper indicates that increased 
glutamine metabolism is associated with poor-prognosis medulloblastoma.  
 
4.3 Glutamine metabolism utilized for imaging and as a therapeutic target 
The high utilization of glutamine by some types of cancer can be exploited for the 
purposes of imagining.  Positron emission tomography (PET) uses a radioactive tracer to 
image metabolic processes.  The most commonly used PET tracer is 18F-
fluorodeoxyglucose (18F-FDG), a modified form of glucose.  When 18F-FDG is 
administered, it is taken up by metabolically active tissues, allowing glucose utilizing 
tissues (such as cancer, if present) to be imaged.   Glucose-based PET scanning is 
commonly used in oncology, and new research suggests utility for glutamine-based PET 
scanning.  Venneti et al created a glutamine-based radioactive tracer—4-18F-(2S,4R)-
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fluoroglutamine (18F-FGln) that allows for imaging of glutamine-utilizing tumors. This 
could prove especially useful in brain tumors where glucose-based PET is impaired by 
the brain’s naturally high level of glucose uptake and utilization (105). 
MYC is one of the most highly amplified and overexpressed oncogenes in all 
types of cancers (106), making it a very attractive therapeutic target.  Directly targeting 
MYC pharmacologically has proven difficult, and no compounds have shown in vivo 
efficacy (107).  The downstream targets of MYC may therefore be better options for 
therapeutic intervention.   Inhibition of glutamine metabolism to treat cancer has been 
explored by a number of different laboratories.  The key enzyme GLS is an especially 
popular target.   
 Several different small molecule inhibitors of GLS have been reported.   BPTES 
has been shown inhibit the growth of Burkitt lymphoma cells in vitro and in vivo (98), 
pancreatic cancer in vitro and in vivo  when used in combination with metformin (108), 
and triple-negative breast cancer cells in vitro when used in combination with cisplatin or 
etoposide (109).  Compound 968 was identified as a glutaminase inhibitor in a screen for 
compounds that inhibited Rho-GTPase induced transformation (110).  Compound 968 
decreased the proliferation of breast cancer cells (110),  and decreased the proliferation 
and migration of non-small cell lung cancer cells in vitro (111).   Ovarian cancer cells 
were sensitive to treatment with compound 968 alone, and compound 968 treatment 
sensitized the cells to the chemotherapy agent paclitaxel (112).   Compound 968 was 
effective against GBM cells resistant to mTOR inhibition (113) and non-small cell lung 
cancer cells resistant to erlotinib (114).   CB-839, the GLS inhibitor produced by 
Calithera Biosciences, demonstrated efficacy against triple-negative breast cancer in vitro 
and in vivo (115).  CB-839 is currently being tested in a clinical trial (NCT02071862) for 
31 
 
patients with advanced solid tumors, including triple-negative breast cancer, non-small 
cell lung cancer, and mesothelioma. As of early 2017, the trial is still ongoing, and it is 
predicted to be completed in September 2017.  Unfortunately, CB-839 does not penetrate 
the blood-brain barrier (115), so it will have no utility in brain tumors such as 
medulloblastoma.  
  Less-specific inhibitors of glutamine metabolism also exist in the form of 
glutamine analogs like 6-diazo-5-oxo-l-norleucine (DON) and Acivicin.   DON is a 
diazo-compound isolated from Streptomyces found in Peruvian soil and shown to inhibit 
the growth of a variety of other bacteria and multiple mouse cancer models (116, 117).  
DON inhibits the activity of several glutamine utilizing enzymes, including those 
involved in purine and pyrimidine synthesis (118-120), GLS (118, 119), NAD synthase 
(118, 121)  and asparagine synthetase (118, 122).   One research group found that DON 
treatment disrupted the morphology of the inner mitochondrial membrane in a carcinoid 
cell line (123).   Another group reported DON could cause single-strand DNA breaks in a 
cell-free setting (124),  suggesting DNA damage as possible DON activity.   In the mid-
1980s and 1990s DON was tested in both adult (125-128) and pediatric (129) clinical 
trials.  These trials were of limited success, most likely because patients were not chosen 
based on any sort of biomarker expression.  Only a few brain tumor patients were 
included in the trials, and DON was not systematically tested against MYC-expressing 
cancers.   
  Acivicin ((2S)-Amino[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]ethanoic acid) 
was identified in 1978 as a fermentation product from Streptomyces sviceus in a screen 
for anti-metabolic compounds that had anti-cancer activity (130).  Like DON, Acivicin  
can inhibit a number of glutamine utilizing enzymes, including those involved in 
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pyrimidine and purine synthesis (131, 132), gamma-glutamyl transpeptidase (133, 134), 
GLS (135), and  glutamate synthase (136).    Acivicin has also be tested in a number of 
adult clinical trials, including trials for colorectal carcinoma (137-139), breast cancer 
(140-142) , mesothelioma (143), non-small cell lung cancer (144-146), and astrocytoma 
(147).  There has been one pediatric clinical trial for patients with refractory solid tumors 
(148).   Like DON, these trials were of limited success, though three brain tumor patients 
in the pediatric trial showed stable disease at the trial’s conclusion (148).  Again, patients 
in these trials were not chose based on any selection criteria that would have predicted 
response to Acivicin. 
 There is legitimate concern about neurological side-effects when using brain-
penetrant glutamine metabolism inhibiting drugs.  Glutamate is the most common 
excitatory neurotransmitter in the brain, and is generated by the activity of GLS.  
Inhibition of glutamate generation in the brain could have serious neurological 
consequences.  Adult patients receiving Acivicin did experience CNS toxicities including 
dizziness, confusion, hallucinations, nightmares, and disorientation.  These symptoms 
resolved after the drug was ceased (137-147, 149-151).   Acivicin CNS symptoms could 
be mitigated by co-administration of an infusion of aminosyn—a solution of electrolytes 
and amino acids (152).   Patients enrolled in the pediatric trial also experienced CNS 
symptoms—somnolence and nightmares—but these symptoms were less severe than 
those seen in adults (148).   Few CNS toxicities were observed in the adult clinical trials 
with DON, and those that were reported were mild (127, 128).   No CNS toxicities were 
reported in children, and side-effects were milder over-all.  Also worth noting, is that the 
maximum tolerated dose (MTD) of DON was never reached in children—making it 
higher than 450mg/m2 (129). 
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CHAPTER 5: RESULTS 
5.1 Medulloblastoma cell lines expressing MYC are sensitive to glutamine metabolic 
inhibitors 
 MYC contributes significantly to the aggressiveness of poor-prognosis Group 3 
medulloblastoma (14), and we sought novel mechanisms for targeting MYC and its 
downstream effectors, in addition to CDK inhibitors and other candidates identified on 
the DiSCoVER screen. Because MYC regulates the expression of key glutaminolytic 
enzymes, including glutaminase (GLS), we hypothesized that MYC-expressing 
medulloblastoma would have abnormal glutamine metabolism (76).   Staining our 
subgrouped-TMA for GLS showed high-level GLS expression (H score >50) in 70% of 
Group 3 tumors, in 40% of SHH tumors and 37.5% of Group 4 tumors (Figure 8A). 
MYC amplification and expression is known to be enriched in Group 3 tumors. We found 
that 100% of tumors on the TMA that expressed MYC by IHC also expressed GLS.  In 
tumors with elevated GLS but low MYC, GLS expression may be regulated by MYCN or 
in a MYC-independent fashion (153-155).   When we investigated the expression of GLS 
in our cerebellar neural stem cell model of medulloblastoma, we found that MYC 
transduced cells also expressed GLS.  In comparison, SV40-immortalized cerebellar cells 
did not express GLS (Figure 8B).   Two patient-derived medulloblastoma cell lines that 
express MYC also express GLS (Figure 8C).  
To target glutamine metabolism, we used two glutamine analogs: Acivicin and 
DON, discussed extensively in Chapter 4.3.  Both Acivicin and DON have been tested in 
Phase I clinical trial in children, but never systematically interrogated in MYC-driven 
malignancies (129, 148).  Treatment with 10uM of Acivicin decreased the growth of 
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D425Med (Figure 9A) and D283Med (Figure 9B) cells as measured by MTS assay.  
Acivicin treatment significantly decreased proliferation in MYC-transformed neural stem 
cells as measured by BrdU incorporation.  Following 10uM Acivicin treatment, the 
percentage of BrdU positive cells dropped from 38% to 11% in cells transduced with 
MYC only (p=0.002 by Student’s t-test) and from 32% to 7% in cells transduced with 
dominant negative TP53, hTERT, AKT and MYC (p=0.016 by Student’s t-test) (Figure 
9C).  The proliferation of human neural stem cells immortalized with SV40 was not 
significantly affected by Acivicin treatment (Figure 9C, p=0.19 by Student’s t-test).   
Acivicin increased apoptosis in cells expressing MYC, as measured by cleaved 
caspase-3 immunofluorescence.  Apoptosis increased from 35% to 65% in human neural 
stem cells transformed with MYC alone (p=0.09 by Student’s t-test),  from 19% to 80% 
in cells transformed with all four oncogenes (p=0.001  by Student’s t-test), from 6% to 
22%  in D425Med cells (p=0.04 by Student’s t-test), and from 3% to 14% in D283Med 
cells (p=0.01 by Student’s t-test) (Figure 9D).   Human stem cells immortalized with 
SV40 were not significantly affected by Acivicin treatment (Figure 9D, p=0.19 by 
Student’s t-test). 
Treatment with 10uM DON also decreased the growth of D425Med (Figure 10A) 
and D283Med (Figure 10B) cells as determined by MTS assay.  10uM DON treatment 
did not decrease proliferation of neural stem cells transformed with MYC, of neural stem 
cells transformed with all four oncogenes, D425Med or D283Med cells (Figure 10C).  
Treatment with DON increased apoptosis in the cerebellar stem cells transformed with 
MYC and in MYC expressing patient-derived cell lines as measured by cleaved caspase-
3 immunofluorescence.  Apoptosis increased from 21% to 33% in neural stem cells 
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transformed with only MYC (p=0.01 by Student’s t-test),  from 11% to 22% in stem cells 
transformed with all four oncogenes (p=0.006 by Student’s t-test), from 6% to 22% in 
D425Med cells (p=0.004 by Student’s t-test), and from 2% to 9% in D283Med cells 
(p=0.04 by Student’s t-test) (Figure 10D).  Human neural stem cells immortalized with 
SV40 did experience significant changes in proliferation (Figure 10C, p=0.99 by 
Student’s t-test) or apoptosis (Figure 10D, p=0.65 by Student’s t-test) after treatment with 
DON. 
 
5.2 Normal human neural stem cells are not sensitive to treatment with glutamine 
metabolic inhibitors 
 Glutamine metabolism is crucial to normal brain function, so there is legitimate 
concern that inhibition could have deleterious effects on patients.  Though Acivicin and 
DON treatment were very well tolerated by pediatric patients and resulted in only 
minimal neurological side-effects (129, 148), we decided to test the effect of Acivicin 
and DON therapy on normal, untransformed, un-immortalized human neural stem cells. 
Neither Acivicin nor DON treatment caused a significant change in proliferation in 
normal human neural stem cells as measured by BrdU incorporation (p<0.37 by Student’s 
t-test, Figure 11A).   Neither compound caused apoptosis as measured by cleaved 
caspase-3 immunofluorescence (p<0.23 by Student’s t-test Figure 11B).   This data 
suggests that glutamine analog therapy will not cause damage to the normal stem cells of 




5.3 Acivicin therapy decreases the size of medulloblastoma flank tumors but did not 
extend survival in animals with orthotopic xenografts  
  We next texted the efficacy of Acivicin as a monotherapy in vivo.  Treatment four 
times a week with a 25mg/kg dose of Acivicin did not extend the survival of mice 
bearing D425Med cerebellar xenografts (p=0.19 by Log-rank test) (Figure 12A).  A 
higher dose of 75mg/kg four times a week also failed to extend survival in mice with 
D425Med orthotopic xenografts (p=0.78 by Log-rank test) (Figure 12B).  The higher 
dose of Acivicin was able to decrease the size of D283Med flank xenografts by 70% 
(Figure 12C).  That Acivicin can successfully reduce the size of flank tumors but not 
extend survival of animals with brain tumors suggests the compound is failing to pass the 
blood-brain barrier.  This is surprising because the neurological side effects observed in 
the Acivicin clinical trials (discussed in Chapter 4.3) suggest that the drug is able to cross 
the blood-brain barrier.  Acivicin is known to have affinity for and is a ligand of the 
Large Neutral Amino Acid Transporter, which is highly expressed in the blood brain 
barrier (156-158).   There may be difference in the blood brain barrier between humans 
and mice which could explain Acivicin’s failure to increase survival of tumor bearing 
mice.  There is also the possibility that a larger dose of drug is needed.  However, the 
limited commercial availability of Acivicin eliminated the possibility of further in vivo 




5.4 DON treatment decreases flank tumor burden and extends survival in mice with 
medulloblastoma orthotopic xenografts 
Once weekly treatment with 30mg/kg of DON dramatically decreased the tumor 
burden of animals with D425Med flank xenografts.  For subcutaneous flank xenograft 
studies, treatment was started after moderately sized tumors were formed. In control 
animals, all tumors increased in volume during the course of the experiment (n=19 
tumors) and in DON treated individuals all the tumors decreased in volume (n=20 
tumors) (Figure 13A).   Mice treated with DON experienced an average 94% decrease in 
flank tumor volume, while control animals experienced a 263% increase in tumor volume 
(p=0.0001, Figure 13B).  This dramatic decrease in tumor burden is shown in Figure 
13C.  In this figure DON treatment began on day 0 (top panel), when all five animals had 
well-established tumors.  After only two weeks (two doses) of treatment, tumor burden 
was dramatically decreased (middle panel).  Four weeks after treatment there are almost 
no detectable tumors (lower panel).  
Weekly DON treatment increased the median survival of mice with orthotopic 
D425Med by 64 days—an increase of 246% (26 days vehicle treated animals vs 90 days 
DON treated animals, p=0.0018 by Log-rank test) (Figure 13D).  We also tested the 
efficacy of DON therapy in mice bearing serially passaged medulloblastoma xenografts.  
The Med211 xenograft has been genetically profiled as a Group 3 medulloblastoma 
tumor.  In animals with Med211 orthotopic xenografts, DON therapy improved median 
survival by 39 days—an increase of 80% (49 days vehicle treated animals vs 88 days 
DON treated animals, p=0.0017 by Log-rank test) (Figure 13E).   
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5.5 An orally available, pro-drug version of DON extends survival of animals with 
medulloblastoma orthotopic xenografts 
 We also tested the efficacy of a DON pro-drug developed by Johns Hopkin Drug 
Discovery (JHDD).   The development of this pro-drug is described in detail in the paper 
by Rais et al (159).   This dual promoeity pro-drug, called JHU-083, has leucine and ethyl 
groups on DON’s carboxylate and amine functionalities to enhance lipophilicity and 
improve brain penetration (Figure 14A).   Unlike unmodified DON, JHU-083 is orally 
bioavailable. After it is administered, JHU-083 is metabolized into DON.   When 
administered to mice in DON-equivalent doses, JHU-083 delivers DON to the plasma at 
a slightly reduced Cmax compared to un-modified DON (Figure 14B).   JHU-083 
treatment (20mg/kg DON equivalent, 3x week) extends the survival of mice with 
D425Med orthotopic xenografts by 33%--21 days for vehicle treated mice vs 28 days for 
pro-drug treated mice (p=0.006 by Log-rank test) (Figure 14C).   Unmodified DON 
administered as a 30m/kg bolus dose extends the survival of mice with D425Med 
orthotopic xenografts by 246% (Figure 13D).   JHU-083 cannot be administered as a 
single 30mg/kg DON equivalent bolus dose due to gut toxicity.  It is possible that the 
dosing of JHU-083 could be increased to 20mg/kg DON equivalent 5x a week, which 
could possibly increase the survival benefit.  It is also possible that the reduced Cmax of 
JHU-083 contributes to the decrease survival benefit provided by JHU-083 compared to 




5.6 Stable isotope metabolomics suggests that DON inhibits glutamine synthetase  
 To investigate the mechanism of DON’s activity in MYC-driven 
medulloblastoma tumors, we performed stable isotope labeled metabolic analysis.  For 
this study, nude mice with established D425Med flank tumors were given one 30mg/kg 
dose of DON or vehicle prior to being injected with uniformly-labeled glucose (13C6-
glucose), uniformly labeled glutamine (13C5-
15N2-glutamine), or vehicle (PBS).   
Metabolites extracted from the tumors were analyzed using LC-MS.  We predicted that 
we would find decreased levels of glutamate in tumors from animals treated with DON. 
Contrary to this predication, we found that glutamate levels remained unchanged in 
tumors treated with DON, suggesting that DON’s primary mechanism of action in 
D425Med tumors is not inhibiting GLS activity (Figure 17A). 
Tumors from animals treated with DON had lower levels of glutamine than 
tumors from vehicle treated animals (Figure 15B).  There are several explanations for this 
result.  DON could be inhibiting a glutamine transporter such as ASCT2, or the activity 
of glutamine synthetase.  In DON treated tumors from animals injected with uniformly 
labeled glucose, we observe a significant decrease in the amount of M+2 glutamate 
isotopologue (p=0.000068 by Student’s t-test, Figure 15C).  In the 13C6-glucose-labeled 
tumors, the C13 carbons in the M+2 glutamate isotopologue are coming from glucose 
entering the TCA cycle in the form of citrate, which is converted to α-ketoglutarate, 
which is converted to glutamate (Figure 15E).   We also observe a significant decrease in 
the M+2 glutamine isotopologue in tumors from DON treated animals labeled with 
uniformly-labeled glucose (p=0.000004 by Student’s t-test, Figure 15D).  The M+2 
glutamine is generated by the enzyme glutamine synthetase from M+2 glutamate (Figure 
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15E).  The reduction in M+2 glutamate and M+2 glutamine in tumors from animals 
treated with DON and subjected to stable isotope labeling with 13C6-glucose suggests that 
glutamine synthetase activity is being inhibited by DON.   
 
5.7 Stable isotope labeling suggests that DON is inhibiting asparagine synthetase 
  Tumors from animals treated with DON had decreased levels of the amino acid 
asparagine (Figure 16A).  Comparing vehicle treated and DON treated tumors from 
animals labeled 13C5-
15N2-glutamine revealed a significant decrease in the level of M+1 
asparagine compared to tumors from vehicle treated 13C5-
15N2-glutamine labeled tumors 
(p=0.016 by Student’s t-test, Figure 16B).   The enzyme asparagine synthetase (ASNS) 
catalyzes the creation of asparagine by joining a nitrogen donated from glutamine to 
aspartate and is a known target of DON (118, 122).   In tumors labeled with 13C5-
15N2-
glutamine, the M+1 asparagine isotopologue is created when an N15 from 13C5-
15N2-
glutamine is added to aspartate (Figure 16C).   The decrease in the M+1 asparagine in 
DON-treated 13C5-
15N2-glutamine labeled tumors indicates that ASNS activity is being 
inhibited by DON.   
 We also observed a significant reduction in M+2 asparagine isotopologue levels 
in tumors from animals treated with DON and labeled with 13C6-glucose compared to 
tumors from vehicle treated,  13C6-glucose labeled mice (p=3.7x10
-9 by Student’s t-test, 
Figure 16D), further suggesting that ASNS is being inhibited.  In the case of 13C6-glucose 
labeled tumors, the M+2 asparagine isotopologue is generated when the 13C6-glucose is 
broken down into 13C2-acetyl co-A and enters the TCA cycle.  This 
13C2-acetyl-CoA is 
eventually converted to 13C2-oxaloacetate, which is converted into 
13C2-aspartate by the 
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enzyme aspartate transaminase.  The resulting 13C2-aspartate is converted into asparagine 
by ASNS generating M+2 asparagine.  (Figure 16E).  If asparagine synthesis was being 
affected at an earlier point, we would expect to observe changes in M+2 aspartate, but 
there was no difference in the level of M+2 aspartate in DON treated-13C6-glucose 
labeled tumors and vehicle treated-13C6-glucose labeled tumors (p=0.40 by Student’s t-
test, Figure 16F).   Asparagine can also be generated by bypassing the TCA cycle when 
pyruvate is converted by pyruvate carboxylase into oxaloacetate rather than acetyl-CoA.  
This oxaloacetate can be converted into aspartate and then asparagine.  If this reaction 
was occurring, we would see M+3 asparagine in 13C6-glucose labeled tumors (Figure 
16E).   There was no detectable M+3 asparagine in either DON or vehicle treated 13C6-
glucose labeled tumors, indicating low pyruvate carboxylase activity in our tumors.   
 
5.8 DON and asparaginase can be combined for enhanced anti-tumor activity 
 Since we found that DON depletes asparagine levels in D425Med tumors (Figure 
16), we decided to test it in combination with asparaginase.  Asparaginase (ASNase) is an 
enzyme that breaks down asparagine into aspartate.  Clinically, it is used to treat acute 
lymphoblastic leukemia, non-Hodgkin’s lymphoma, and other hematologic malignancies 
(160).    In D425Med medulloblastoma cells, a combination of ASNase and DON was 
more effective at reducing growth than either drug line alone (Figure 17A).   The 
combination of DON and ASNase increased the percentage of cleaved caspase-3 positive 
cells more than either drug alone in D425Med cells—an average of 6% cleaved caspase-3 
positive cells in vehicle treated cells, 16% in DON treated cells, 5% in ASNase treated 
cells, and 23% in combination treated cells (Figure 17B, vehicle vs combination treated 
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p=0.015 by Student’s t-test).  In human neural stem cells transformed wit MYC, the 
combination treatment increased the percentage of cleaved caspase-3 cells more than 
either drug alone—an average of 21% in vehicle treated cells, 21% in DON treated cells, 
17% in ASNase treated cells and 33% in combination treated cells (Figure 17C).   In 
human neural stem cells transformed with MYC, DNp53, hTERT and AKT the 
combination therapy was particularly effective.   The average percent cleaved caspase-3 
positive cells was 9% in vehicle treated cells, 15% in DON treated cells, 15% in ASNase 
treated cells, and 64% in combination treated cells (Figure 17D, vehicle vs combination 
treated p=0.00006 by Student’s t-test).   The increased efficacy of the DON and 
asparaginase therapy is most likely due to DON and ASNase working in concert to 












CHAPTER 6:  DISCUSSION 
 
Another therapeutic target presented in this dissertation is glutamine metabolism.  
Multiple cancers are thought to have aberrant glutamine metabolism (76-81), and 
inhibiting glutaminase is an attractive therapeutic option in MYC-driven 
medulloblastoma.  The glutamine analogs DON and Acivicin are known to inhibit a 
variety of glutamine utilizing enzymes, including GLS and those involved in nucleic acid 
biosynthesis (118-122, 130-136).  Inhibiting glutamine metabolism at multiple levels 
with either DON or Acivicin may lead to a decreased likelihood of developing resistance.  
Additionally, these drugs could be used as part of personalized therapy for patients with 
Group 3 tumors in association with chemotherapy and radiation 
  Because neurons use GLS to synthesize glutamate for use as a neurotransmitter, 
there is concern that glutaminase inhibitors may cause neurotoxicity. Phase I pediatric 
clinical trials of Acivicin reported somnolence and nightmares as a major side effect – 
however these were moderate and reversible after stopping treatment (148).  The lack of 
toxicity of DON and Acivicin against normal human neural stem cells and SV40-
immortalized cells suggests that the normal cells of the pediatric brain would not be 
harmed by DON or Acivicin treatment and the drugs will selectively kill tumor cells.  
The most serious side effect in phase I trials of DON and Acivicin was 
myelosuppression.  Other side effects, like nausea and vomiting, were easily managed 
and all symptoms resolved after the cessation of therapy (129, 148). The maximum 
tolerated dose for DON was never reached in a pediatric oncology phase I trial, 
suggesting that there is significant therapeutic index for this drug (129).  In the Acivicin 
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trial, of the eight pediatric patients with brain tumors who were enrolled, three had stable 
disease at the cessation of the trial (148).  
Based on the pre-clinical data presented here, we believe these compounds will be 
most successful against MYC-dependent cancers.  Another concern with systemically 
delivered drugs is their ability to penetrate the blood-brain barrier.  The CNS side-effects 
of somnolence and nightmares suggest that the drugs successfully penetrate the blood-
brain barrier. DON and Acivicin have been shown to have affinity for and are ligands of 
the Large-neutral Amino Acid Transporter, a transporter highly expressed in the BBB 
(156-158).  This evidence suggests that Acivicin and DON are transported across the 
blood-brain barrier.   Though unmodified DON is capable of crossing the blood brain 
barrier, Johns Hopkins Drug Discovery has been developing orally available, pro-drug 
versions of DON that enhance brain delivery (159).  The pro-drug form of DON JHU-
083 was demonstrated here to have efficacy in medulloblastoma.  Pro-drug versions of 
DON with improved brain penetration could further enhance DON’s clinical utility.  
Providing additional support for the role of glutamine metabolism in 
medulloblastoma is the finding that high levels of glutamate in medulloblastoma tumors 
as measured in vivo by magnetic resonance spectroscopy (MRS) are associated with 
decreased survival (104).  Increased levels of glutamate in high risk medulloblastoma 
suggest activity of and potential sensitivity to glutamine anti-metabolites such as DON or 
Acivicin.  MRI spectroscopy may represent a potential non-invasive method for 
identifying patients who could benefit from glutamine metabolism inhibition.   
Using stable isotope metabolomics we determined that in D425Med 
medulloblastoma tumors, DON is most likely acting through inhibition of glutamine 
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synthetase and asparagine synthetase.   The enzyme asparaginase reduces asparagine 
levels by converting asparagine into aspartate and ammonia and is used clinically for 
hematologic malignancies. We found that the in our medulloblastoma models, the 
combination of DON and asparaginase increased apoptosis more than either compound 
alone, presumably because of an even larger decrease in asparagine levels.  This data is 
consistent with previous work by Zhang et al, which showed depletion of asparagine led 
to increased apoptosis.  They found that when asparagine levels are low, the ATF4 
protein interacts with CHOP and XBP1 to trigger apoptosis (97).  We predict that the 
combination of DON and asparaginase would increase survival more than either 
compound alone in animals bearing MYC-driven medulloblastoma tumors.  Though the 
in vivo studies have yet be conducted, the in vitro data presented here is very encouraging 
and further investigation into this drug combination is warranted.   
In conclusion, this dissertation presents data that shows that glutamine analogs 
have efficacy in in vitro and in vivo models of Group 3 medulloblastoma.  This data 
provides preclinical justification for the testing of DON therapy in carefully selected 









CHAPTER 7: METHODS 
7.1 Generation of a Cerebellar Neural Stem and Progenitor Cell Model of Group 
3/C1 Medulloblastoma 
Human cerebellar neural stem cells were derived as described (46).   Human 
neural stem and progenitor cells were obtained in concordance with German law and 
Ethics Board evaluation. The study was also approved by the Johns Hopkins Institutional 
Review Board. The cells were obtained by dissecting the cerebellar anlage and then 
culturing as neurospheres.  The neural stem and progenitor neurospheres were transduced 
using lentiviral and retroviral vectors carrying genetic elements of interest.  R248W-TP53 
(Addgene plasmid 16437) and MYC (Addgene plasmid 17758) were subcloned into 
pWPI (Addgene 12254) (161).   For hTERT, Addgene plasmid 12245 was used.  The 
SV40 plasmid is described in Raabe et al (162).  For constitutively active AKT, the 
retroviral Addgene plasmid 15294 was used.   Lentivirus was produced by transfecting 
293T cells with VSV-G envelope plasmid, Δ8.9 gag/pol plasmid and the plasmid 
containing the gene of interest as described in (162) using FuGene (Roche) per 
manufacturer’s instruction.  Retrovirus was produced by transfecting 293T-GP cells with 
VSV-G plasmid and the plasmid containing the gene of interest.  24 hours post 
transfection, 293T cells were switched to EGF-FGF media and the supernatant was 
collected at 48 and 72h.   The collected supernatant was filtered with a 0.45 micron filter 
and stored at -80C until use.     
Cerebellar neural stem cells were dissociated using Accutase (Sigma) and gentle 
trituration, then incubated with viral MYC; SV40; or MYC, hTERT and DNp53 viral 
supernatants for 24 hours.  After approximately one week in culture, spheres were 
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identified and individually placed into wells of 96-well plates.  After visually verifying 
that only a single sphere was in each well, the spheres were broken into single cells by 
trituration and expanded.  Expression of the introduced oncogenes was verified by 
western blot and qPCR.  Cells successfully transduced with MYC, hTERT and DNp53 
were then incubated with AKT viral supernatant for 24 hours.  The cells were then placed 
under puromycin selection for 72 hours, following which sub-clones were generated as 
described above.  
 
7.2 Cell Culture 
The neural stem cell lines grow as neurospheres in media composed of 30% 
Ham’s F12, 70% DMEM, 1% antibiotic antimycotic, 20% B27 supplement, 5ug/mL 
heparin, 20ng/mL EGF, and 20ng/mL FGF2.  Lines transformed with AKT are grown 
under 0.2ug/mL puromycin selection. The human medulloblastoma cell lines D425Med 
and D238Med were both established at Duke University (163).  D283Med is available 
through ATCC.   Both lines are cultured in MEM media supplemented with 10% FBS.  
All cells were verified to be mycoplasma free by PCR testing. Cell line identity testing by 




 Brains were removed from mice immediately following euthanasia and fixed in 
10% buffered formalin.  The brains were processed and H&E slides prepared by the 
Johns Hopkins Pathology Reference Lab.    
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7.4 Immunohistochemistry/Tissue Microarray 
 IHC was performed on deparaffinized sections of brain xenografts as described 
(161).  The following primary antibodies were used: human specific NESTIN (1:500; 
Millipore, #MAB5326); GFAP (1:1000; DAKO #Z0334); MAP2 (Santa Cruz #20172); 
MYC (1:300, Epitomics #14721); phospho-AKT (1:50, Cell Signaling Technologies); 
TP-53 (Sigma, #BP-5312), and phospho-RB (1:250, Cell Signaling Technologies 
#D20B12). For the TMA of 65 primary medulloblastoma samples, IHC was performed 
on deparaffinized arrays followed by antigen retrieval, using MYC, phospho-AKT, and 
GLS antibodies at dilutions of 1:300, 1:70, and 1:50, respectively. The GLS antibody is 
from ProteinTech (#12855-1-AP), respectively. The array was stained for TP53 by Johns 
Hopkins Clinical Pathology following a Ventana F standard protocol.  The TMA was 
scored by intensity (scale of 0 to 2) and percentage stained; an H-score was calculated by 
multiplying intensity by percentage of cells positive.   
 
7.5 Gene Expression Analysis 
RNA was extracted from cells and xenograft tumors using TRIZOL according to 
manufacturer’s directions. RNA was assessed for quality and integrity using a 
Bioanalyzer (Agilent Technologies) and samples had a RNA Integrity Number score of 
higher than 8.2 (164).  Gene expression data was generated using Affymetrix High 
Throughput (HT) U1332+ Chip (Santa Clara, CA) according to manufacturer’s 
guidelines.  Raw data was processed and analyzed using GenePattern as previously 





7.6 DiSCoVER Analysis Method 
The main analysis components of DiSCoVER are shown in Figure 18. The 
murine xerographs of human neural stem cells transformed with DNp53, hTERT, AKT 
and MYC (hNSC G3) and controls were profiled using Affymetrix arrays (see Gene 
expression analysis above). The gene probe identifiers were mapped into gene symbols 
using the Collapse Dataset tool (“max probe”) of the GSEA software (166).  The top 150 
up-regulated genes between the murine xenographs of transformed hNSC G3 samples 
and controls were used to create an hNSC G3 oncogenic transcriptional signature (Table 
1). We used this gene set to project two large mRNA expression datasets, The Cancer 
Cell Line Encyclopedia (CCLE) (167) and the Sanger Dataset (168).  This projection is 
made using single-sample GSEA (169) to produce enrichment profiles of the hNSC G3 
signature in each sample of those datasets. Once this projection is completed we match 
the signature profile vs. drug sensitive profiles corresponding to drug sensitivity datasets: 
The Cancer Therapeutics Response Portal (CTRP v2) (170), the CCLE Pharmacological 
Profiling Drug Data (167); and The Genomics of Drug Sensitivity in Cancer (168). 
Therefore there are three comparisons we performed between the transcriptional profile 
of the hNSC G3 signature and the drug sensitivity profiles (see Figures 18 and 19, 
Comparison I, II and III).  There are only two mRNA datasets because the CCLE and 
CTRP v2 sensitivity datasets share the same mRNA samples. The matching scores 
between the signature, and each drug sensitivity profile, were computed using the 
Information Coefficient (IC), an information theoretic-measure of association, similar to 
the measure of association we used in Abazeed et al. 2013 (171) to compare radiation 
sensitivity vs. pathway expression. Once we obtained the matching scores of each drug 
against the hNSC G3 signature, we performed a permutation test on the signature profile 
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with 10,000 permutations. These values are used to create an empirical null distribution 
from which nominal p-values and False Discovery Rates (FDR) (172) are computed.  
We focus in the top scoring compounds with FDR below 0.33 in the three 
comparisons and look for overlaps in compounds or compound classes (Tables 2-4). This 
is the way we noticed the appearance of CDK inhibitors for each dataset (Figure 4B and 
Figure 19). In Figure 19 we show that CDK inhibitors are top hits in the 3 drug sensitivity 
datasets by plotting the Information score (IC) in the y-axis and the correlation 
coefficient (between signature and drugs) in the x-axis. This comparison of correlation 
vs. information coefficients provides supplementary information about how linear or non-
linear is the relationship between the signature and a given drug. The DiSCoVER method 
will be made publicly available as an analysis module in GenePattern 
(www.genepattern.org). 
 
7.7 In vitro Drug Treatments 
Palbociclib and flavopiridol were purchased from Sellekchem and diluted 
according to manufacturer’s instructions. DON and Acivicin were purchased from Sigma 
and Bachem and diluted according to manufacturer’s instructions. 
 
7.8 BrdU Incorporation Assay 
Cells were pulsed with 100 uM of bromodeoxyuridine (BrdU) for the last 6 hours 
of drug treatment then fixed in cytospin fluid and spun onto glass slides using a 
cytocentrifuge.  Cells were permeabilized in 0.1% Triton X, DNA denatured in 2N HCl,  
blocked in 5% normal goat serum, and incubated with anti-BrdU antibody diluted 1:500 
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(Sigma, clone BU-33), followed by secondary antibody conjugated to Cy3 diluted 1:500 
(Jackson ImmunoResearch). DAPI was used as a counterstain.  Three DAPI and the 
corresponding Cy3 images were taken for each slide.  The number of DAPI and Cy3 
positive cells were counted using Adobe® Photoshop®.  For each pair of images, the 
percent of Cy3 positive cells was calculated.  The average Cy3 positivity was determined 
by calculating the average of at least three pairs of images for each treatment.  Images 
were blinded before counting. 
 
7.9 Cleaved Caspase-3 Immunofluorescence 
 Following drug treatment, cells were fixed in cytospin fluid and spun onto glass 
slides using a cytocentrifuge.  Cells are permeabilized in 0.1% TritonX, blocked in 5% 
normal goat serum, and incubated with anti-cleaved caspase 3 antibody diluted 1:400 
(Cell Signaling Technology®, clone 5A1E), followed by a secondary antibody 
conjugated to Cy3 diluted 1:500 (Jackson ImmunoResearch). Cells were scored for 
apoptosis similarly to the method used for BrdU incorporation.   
 
7.10 Western Blot 
Protein was extracted by lysing cell pellets with RIPA buffer and quantified using 
a Bradford Assay.  Protein samples were run on 4 to 12% Bis-Tris gels.  Antibodies 
against GAPDH (6C5: sc-32233), Actin (C4: sc-47778) and MYC (9E10: sc-40) were 
obtained from Santa Cruz Biotechnology®.  Antibodies for GFAP (#3670), total Rb 
(#9309), Phospho-Rb Ser780 (#8180), Phospho-Rb Ser807/811 (#8516), and cleaved-
PARP (#5625) are from Cell Signaling Technology. The Nestin (10C2, MAB5326) and 
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SOX2 antibodies are from Millipore.  The GLS antibody is from ProteinTech (#12855-1-
AP).  The following antibody dilutions were used:  GAPDH (1:1000), Actin (1:1000), 
MYC (1:1000), GFAP (1:2000), Sox2 (1:200), Nestin (1:1000), total Rb (1:1000), 
phospho-Rb Ser780 (1:1000), phospho-Rb Ser807/811 (1:1000), cleaved-PARP (1:800), 
GLS (1:1000)  Peroxidase labeled secondary antibodies were diluted 1:5000 and are from 
KPL or Cell Signaling Technologies. 
 
7.11 Metabolomics  
Flank tumors were flash frozen in liquid nitrogen immediately after animal 
euthanasia.  Tumors were manually homogenized in liquid nitrogen using a mortar and 
pestle chilled by dry ice and liquid nitrogen.  Tumors and the resulting homogenized 
powder were kept chilled on dry ice at all times.  As the flank tumors were very large, an 
aliquot of tumor powdered was weighed and the extraction performed on the aliquot.  
Samples were incubated at -80C with 5 volumes of 80% ice-cold HPLC grade methanol 
to extract metabolites.  Before LC/MS analysis, samples were spun down at top speed in 
a chilled centrifuge to prevent protein contamination. 
After extraction, samples were analyzed using an Agilent 6550 Q-TOF with a 
Waters Acquity UPLC. Data analysis was performed using MAVEN, an open-source 
metabolomics software program developed at Princeton (173, 174).  Isotopomer 
distribution was determined as percent incorporation into the entire metabolite pool 




7.12 Quantification of DON 
The concentration of DON in plasma was determined as described in Rais et al 
(159). 
7.13 In vivo studies  
 7.13a Orthotopic xenograft procedure 
All xenografting was conducted in female nude (Nu/Nu) mice at approximately 6 
weeks of age from Charles River Labs.  Prior to implantation of cells, animals were 
anesthetized using a mixture of 10% ketamine and 5% xylazine.  For orthotopic 
xenografts, the scalp was opened with a sterile blade and a burr hole was made in the 
skull 1mm to the right and 2 mm posterior of the lambdoid suture with an 18 gauge 
needle.  The needle of a Hamilton syringe was inserted 2mm into the brain using a 
stereotactic guide and 100,000 cells in 2 to 5uL of media were injected into the 
cerebellum.  After the cells were injected, the scalp incision was closed with sutures.   
7.13b Flank xenograft procedure 
All xenografting was conducted in female nude (Nu/Nu) mice at approximately 6 
weeks of age from Charles River Labs. Prior to injection, animals were anesthetized with 
a mixture of 10% ketamine and 5% xylazine. One million cells suspended in 200uL of a 
50:50 mix of Matrigel (Corning) and media were injected for each flank tumor.  Cells 
were injected using an 18 gauge needle.  One tumor was implanted behind each limb, so 
each mouse carried four flank tumors.  All animals were monitored daily.  Flank tumors 
were measured while mice were lightly anesthetized using digital calipers and tumor 
volume calculated using the formula width2 x length x 0.52 (11).  
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7.13c Drug treatments 
 Palbociclib was prepared in a pH 4.0 50mM sodium lactate solution and 
administered by oral gavage in a 100uL bolus. Animals received a 150mg/kg dose 5x a 
week, which is a widely used dosing schedule in pre-clinical murine xenograft models 
(56, 59, 60, 69).  DON and Acivicin were obtained from Sigma and Bachem, prepared in 
PBS and administered as a 300uL IP injection.  For DON, animals received 30mg/kg 
dose once per week.  For Acivicin, animals received 25 or 75mg/kg doses four times a 
week.  All animals were monitored daily.  Symptomatic animals were euthanized and 
their brains or flank tumors removed and fixed in formalin.   
7.13d Stable isotope labeling procedure 
One hour prior to labeling, animals were give a single 30mg/kg dose of DON.  
Uniformly labeled glutamine was prepared at a 100uM concentration in PBS and 
uniformly labeled glucose was prepared as a 20% solution in PBS.   Animals were given 
three 100uL IP injections of isotope spaced 15 minutes apart.  Euthanasia occurred two 
hours after second isotope injection.  At the time of euthanasia blood was collected by 
cardiac puncture.  Tumors were immediately removed and flash frozen in liquid nitrogen.  
The final blood sample was spun down in a chilled (4C) centrifuge at 3,500g for 15 
minutes to separate red blood cells from plasma.  The plasma was flash frozen in liquid 
nitrogen.   All uniformly labeled isotopes were obtained from Cambridge Isotope Labs.  
7.13e Study Approval  
For animal care and anesthesia, "Principles of laboratory animal care" (NIH publication 
No. 8623, revised 1985) was followed, using a protocol approved by the Johns Hopkins 
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Animal Care and Use Committee, in compliance with the United States Animal Welfare 
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Table 1: The 150 genes that make up the hNSC G3 signature 
C11ORF70 SPEN C20ORF117 TEAD4 
RPLP1 DCUN1D5 RPL30 FLJ90086 
ZNF207 B3GNT3 SH3RF2 RPS18 
WNT10B MTRR HECTD1 LRRC57 
KIAA1598 TRMT1 USP54 BXDC5 
TCERG1 ANAPC10 LOC285346 ATP5O 
OSGEPL1 PAK1 ZNF511 NARS2 
THBS2 IKBKAP LOC440087 CD3EAP 
LOC196264 CHCHD2 PARVB PSMD12 
RCOR2 HSF1 PSMA6 TYW3 
BDP1 KIAA1875 EIF2S2 ITLN1 
FUSIP1 ALPK3 C4ORF15 MGC12965 
BANF1 LOC390874 DEPDC6 PGRMC1 
ZF RPL5 CCDC45 ZNF544 
UCHL3 MYL9 RELN TCHP 
PDCD2 SKIV2L2 ARS2 NAT10 
MECR MRPL45 ACSL4 ORC2L 
C12ORF52 SAE1 MRPL9 INTS1 
C1ORF67 SLC22A18AS DYRK2 ST6GALNAC1 
C1ORF37 HISPPD1 SLC19A1 CD48 
PEF1 KLHL21 MARK2 MYSM1 
UBE2M RAB3IL1 EXOSC5 LOC388796 
KAZALD1 LOC221711 ACSL5 GJA3 
GSR LOC285627 TMEM123 ADRB3 
HDAC1 BMPR1B LOC340178 C1ORF109 
B4GALT3 NCOA6IP WDR35 LOC340061 
NUP50 RNF168 NUP160 PEBP1 
MID1IP1 CXCL13 DKC1 ZBTB48 
AHSG RPP25 KIAA1333 HEATR2 
SPATA5L1 C4ORF14 PAWR ZNF529 
DOCK9 FLJ39779 ST6GAL1 RPL7A 
TTF2 BNIP2 IQCA FLJ43944 
FAM58A CDK4 CCDC99 GCN5L2 
DEPDC1B FLJ44606 SP4 RAB3A 
CALML4 C15ORF45 MEF2C SLC5A10 
PTGER2 EXOSC8 C9ORF105 SELI 
AHI1 KCNH3 AMBN NOL11 




Table 2: The top 30 hits from the DiSCoVER analysis of the Cancer Therapeutics Response Portal (CTRP v2) database. Cyclin 
Dependent Kinase inhibitors are highlighted. 











1 BRD-K30748066 inhibitor of CDK9 0.421 0.00178 0.227 *
2 linsitinib inhibitor of insulin-like growth factor 1 receptor and insulin receptor (IGF1R;INSR) 0.419 0.00194 0.227 *
3 BRD-K42260513 inhibitor of enhancer of zeste polycomb repressive complex 2 subunit (EZH2) 0.414 0.00245 0.227 *
4 BRD-K01737880 - 0.411 0.00275 0.227 *
5 BRD-K09344309 - 0.411 0.00278 0.227 *
6 GSK-J4 inhibitor of lysine-specific demethylases (KDM6A;KDM6B) 0.411 0.00283 0.227 *
7 sotrastaurin inhibitor of protein kinase C beta (PRKCB) 0.404 0.00379 0.261 *
8 BRD-K88742110 inhibitor of HDAC8 (HDAC8) 0.397 0.00502 0.294 *
9 Compound 1541A activators of executioner procaspases 3, 6, and 7 (CASP3/6/7) 0.393 0.00595 0.294 *
10 dabrafenib inhibitor of BRAF 0.388 0.00719 0.294 *
11 brivanib inhibitor of VEGFR 1/2 (FLT1;KDR) 0.387 0.00732 0.294 *
12 SR8278 antagonist of Rev-ErbAalpha (NR1D1) 0.386 0.0078 0.294 *
13 Mdivi-1 inhibitor of dynamin 1; inhibitor of mitrochondrial division inhibitor (DNM1) 0.382 0.00904 0.294 *
14 QS-11 inhibitor of GTPase activating protein of ARF 1 (ARFGAP1) 0.376 0.011 0.294 *
15 alvocidib inhibitor of cyclin-dependent kinases (CDK1/2/4/6) 0.375 0.0115 0.294 *
16 BRD-K02251932 product of diversity oriented synthesis 0.375 0.0117 0.294 *
17 cytarabine hydrochloride inducer of DNA damage 0.374 0.012 0.294 *
18 chlorambucil DNA alkylator 0.373 0.0124 0.294 *
19 BRD-K13999467 product of diversity oriented synthesis 0.373 0.0125 0.294 *
20 IU1 inhibitor of the deubiquitinase activity of USP14 0.369 0.0141 0.294 *
21 GSK461364 inhibitor of polo-like kinase 1 (PLK1) 0.369 0.0143 0.294 *
22 methotrexate inhibitor of dihydrofolate reductase (DHFR) 0.369 0.0143 0.294 *
23 necrostatin-7 inhibitor of necroptosis 0.368 0.0144 0.294 *
24 docetaxel inhibitor of microtubule assembly 0.367 0.0152 0.294 *
25 leptomycin B inhibitor of exportin 1 (XPO1) 0.366 0.0155 0.294 *
26 imatinib inhibitor of BCR-ABL1 and c-KIT (ABL1;BCR;KIT) 0.365 0.0159 0.294 *
27 BMS-195614 antagonist of retinoic acid receptors (RARA;RARB;RARG) 0.364 0.0166 0.296 *
28 SCH-79797 antagonist of proteinase-activated receptor 1 (PAR1) (F2R) 0.363 0.0174 0.299 *
29 VX-680 inhibitor of aurora kinases (AURKA;AURKB;AURKC) 0.361 0.0183 0.303 *
































Table 3:  The top 24 hits from the DiSCoVER analysis of the Pharmacological Profiling Drug Data (CCLE) database. Cyclin 
Dependent Kinase inhibitors are highlighted. 











1 Paclitaxel    Microtubule-Stabilizing Agent 0.38 0.0116 0.181 *
2 Irinotecan    DNA Topoisomerase I Inhibitor 0.364 0.0199 0.181 *
3 Topotecan    DNA Topoisomerase I Inhibitor 0.355 0.0255 0.181 *
4 PD-0332991    inhibitor of cyclin-dependent kinases (CDK1/2/4/6) 0.341 0.0365 0.181 *
5 PF2341066    c-MET and ALK Inhibitor 0.339 0.0378 0.181 *
6 PHA-665752    c-MET Inhibitor 0.321 0.06 0.24 *
7 L-685458    gamma-Secretase Inhibitor 0.31 0.0776 0.266 *
8 17-AAG    Heat Shock Protein 90 (hsp90) Inhibitor 0.291 0.116 0.348
9 Panobinostat    Histone Deacetylase (HDAC) Inhibitor 0.283 0.134 0.359
10 AZD6244    MEK1 and MEK2 Inhibitor 0.254 0.203 0.473
11 PD-0325901    MEK1 and MEK2 Inhibitor 0.245 0.227 0.473
12 Sorafenib    Multi-kinase inhibitor 0.239 0.243 0.473
13 TAE684    ALK Inhibitor 0.229 0.272 0.473
14 TKI258    Multi-kinase inhibitor 0.227 0.28 0.473
15 RAF265    Raf kinase B and KDR Inhibitor 0.22 0.301 0.473
16 AEW541    IGF-1R Inhibitor 0.217 0.316 0.473
17 Nilotinib    Abl Inhibitor -0.219 0.309 0.181
18 Nutlin-3    MDM2 Inhibitor -0.275 0.154 0.181
19 AZD0530    Src and Abl inhibitor -0.275 0.154 0.181
20 ZD-6474    Multi-kinase inhibitor -0.277 0.151 0.181
21 Lapatinib    EGFR and HER2 Inhibitor -0.29 0.12 0.181
22 LBW242    Inhibitor of Apoptosis Proteins (IAP) Inhibitor -0.343 0.0355 0.181
23 Erlotinib    EGFR  Inhibitor -0.352 0.0279 0.181






























Table 4: The top 30 hits from the DiSCoVER analysis of the Genomics of Drug Sensitivity Cancer (Sanger) database. Cyclin 
Dependent Kinase inhibitors are highlighted. 










1 Methotrexate_ALPHA inhibitor of dihydrofolate reductase (DHFR) 0.607 7.85E-06 0.012 *
2 JW-7-52-1_D inhibitor of MTOR 0.572 5.41E-05 0.0282 *
3 Z-LLNle-CHO_B inhibitor of g-secretase 0.568 6.48E-05 0.0282 *
4 BMS-509744_B inhibitor of ITK 0.556 0.000114 0.0282 *
5 A-443654_B inhibitor of AKT 0.554 0.000127 0.0282 *
6 Paclitaxel_B microtubule inhibitor 0.546 0.000174 0.0282 *
7 GNF-2_B inhibitor of BCR-ABL 0.542 0.000207 0.0282 *
8 BCR-ABL_B inhibitor of ABL, SRC, KIT, PDGFR 0.542 0.000211 0.0282 *
9 CGP-082996_B inhibitor of cyclin-dependent kinase (CDK4) 0.541 0.00022 0.0282 *
10 CGP-60474_B nhibitor of cyclin-dependent kinases (CDK2/4/5/7/9) 0.541 0.000221 0.0282 *
11 WH-4-023_B inhibitor of SRC family, ABL 0.538 0.000244 0.0282 *
12 Sunitinib_B inhibitor of PDGFRA, PDGFRB, KDR, KIT, FLT3 0.537 0.000254 0.0282 *
13 JW-7-52-1_B inhibitor of MTOR 0.536 0.000265 0.0282 *
14 AZD-0530_ALPHA inhibitor of SRC, ABL1 0.535 0.000277 0.0282 *
15 BI-2536_B inhibitor of PLK1, PLK2, PLK3 0.533 0.000291 0.0282 *
16 WZ-1-84_B inhibitor of BMX 0.533 0.000295 0.0282 *
17 A-770041_B inhibitor of SRC family 0.531 0.000315 0.0282 *
18 BMS-536924_B inhibitor of IGF1R 0.53 0.000331 0.0282 *
19 Doxorubicin_D DNA intercalating 0.526 0.000375 0.0284 *
20 BMS-754807_D inhibitor of IGF1R 0.525 0.000403 0.0284 *
21 VX-680_B inhibitor of Aurora A/B/C, FLT3, ABL1, JAK2 0.524 0.000413 0.0284 *
22 AP-24534_ALPHA inhibitor of ABL 0.523 0.000423 0.0284 *
23 S-Trityl-L-cysteine_B inhibitor of KIF11 0.523 0.000427 0.0284 *
24 XMD8-85_B inhibitor of ERK5 (MK07) 0.513 0.000611 0.0374 *
25 CMK_B inhibitor of RSK 0.512 0.000633 0.0374 *
26 Lapatinib_B inhibitor of EGFR, ERBB2 0.512 0.000645 0.0374 *
27 AP-24534_B inhibitor of ABL 0.511 0.00066 0.0374 *
28 GW843682X_B inhibitor of PLK1 0.51 0.000687 0.0374 *
29 Vinorelbine_B microtubule inhibitor 0.508 0.00074 0.0374 *



































Figure 1: Creation of a human neural stem cell model of medulloblastoma  
 
A) Diagram illustrating the creation of novel cancer models using human stem cells and 
oncogenic elements of interest.  B) Human cerebellar neurosphere.  C)  Western blot 
indicating the expression of stem cell markers in the human cerebellar neural stem and 
progenitor cells. D) 65-sample medulloblastoma tissue microarray (TMA) reveals that 
Group 3 samples have the highest MYC expression.  Lower panel: an example of MYC 
staining in a Group 3 sample.  E)  Staining the TMA reveals that Group 3 samples also 
have the highest expression of TP53, indicating inactivation of this pathway.  Lower 
Panel: an example of TP53 staining in a Group 3 sample. F)  Phospho-AKT, which 
indicates activation of AKT, is expressed in all three subgroups present on the array.  
Lower panel: an example of Phospho-AKT staining in a Group 3 sample.  Magnification 








Figure 2: Human neural stem cells transformed with oncogenes associated with 
aggressive medulloblastoma form tumors that resemble primary human medulloblastoma 
 
A) Stem cells transduced with MYC have increased proliferation compared to 
untransduced neural stem cells and those immortalized with SV40.  B) Cerebellar neural 
stem cells transduced with DN-TP53 hT AKT and MYC form tumors that kill mice in 
117 days.  Cells transduced with SV40 alone do not form tumors.  C) These tumors 
express the introduced oncogenes.  Images show tumor adjacent to normal brain. 200x 
magnification.  D) Tumors formed from cerebellar neural stem cells transduced with all 
four oncogenes form aggressive, anaplastic tumors (i, 400x) that spread to the 
leptomeninges (ii, 200x) and metastasize to the spine (iii, 200x).  E) The tumors are 










Figure 3: Human neural stem cell models of medulloblastoma are genetically similar to 
Group 3 medulloblastoma tumors  
 
Human neural stem cell models of medulloblastoma have similar expression profiles to 
the aggressive C1 component of Group 3.  Red indicates high expression and blue 
indicates low expression of curated gene sets in A, B.  A) C1 samples have high levels of 
the gene sets indicated by the green box.  Subtype specific gene sets are separated by 
yellow lines.  Patient expression from data from Cho et al, 2011 (11).  B) A close up of 
the human neural stem cell heat man indicates that increasing the number of oncogenes 
increases the expression of C1 associated gene sets.  The samples most highly expressing 
C1-associated gene sets are from intracranial xenografts.  C) An association metric 
compares the pathway enrichment subtypes (columns) to xenografts and cell models 






Figure 4: The DiSCoVER technique reveals CDKs as a potential therapeutic target for 
Group 3 medulloblastoma 
  
A) Diagram showing a summary of the most important steps in the DiSCoVER analysis 
method. B) Selected cyclin-dependent kinase inhibitor results from the three drug 
sensitivity datasets. The samples are sorted from high to low enrichment scores of the 
hNSC G3 signature as indicated by the grey bar. The heatmaps indicate relative viability, 
and thus sensitivity, with blue indicating sensitivity to the indicated drug (less viable) and 
red indicating resistance to the indicated drug (more viable). Cells expressing a high level 
of the hNSC G3 signature tend to be more sensitive to these compounds. Values on the 












Figure 5: Medulloblastoma cells expressing MYC are sensitive to palbociclib treatment 
 
A) 24h treatment with palbociclib (PD) causes decreased phosphorylation of Rb in 
D425Med, D283Med, cerebellar derived human neural stem cells transformed with four 
oncogenes and neural stem cells transformed with only MYC. SV40 immortalized cells 
were not included because Rb function is disabled by the large T antigen. Numbers 
represent the level of Rb phosphorylation as a percentage of total Rb normalized to the 
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control. All values were also normalized to Actin. Quantification performed in ImageJ. 
B) 72h treatment with PD causes decreased proliferation in MYC-expressing 
medulloblastoma cell lines as determined by BrdU incorporation. BrdU incorporation 
was determined by immunofluorescence. Results are from three independent 
experiments. Bars show mean and SEM. *P<0.05 by Student’s t-test.  Lower panel shows 
representative images. Red cells are positive for BrdU.  All cells were counterstained 
with DAPI (blue). C) 24h PD treatment causes increased expression of cleaved-PARP, 
indicating cell death by apoptosis. D)  PD treatment (72h) induces apoptosis. Apoptosis 
was determined by immunofluorescent staining for cleaved caspase-3. Results are from 
three independent experiments. Bars show mean and SEM. *P<0.05 by Student’s t-test.  
Lower panel shows representative images.  Red cells are positive for cleaved caspase-3.  




































Figure 6: Medulloblastoma cells expressing MYC are sensitive to flavopiridol  
 
 72h treatment with the pan-CDK inhibitor flavopiridol causes decreased proliferation in 
MYC-expressing medulloblastoma cell lines as determined by BrdU incorporation. BrdU 
incorporation was determined by immunofluorescence. Results are from three 
independent experiments. Bars show mean and SEM *P<0.05 by Student’s t-test.  The 
lower panel shows representative images.  Red cells are positive for BrdU. All cells were 
counterstained with DAPI (blue). B) Flavopiridol treatment (72h) induces apoptosis. 
Apoptosis was determined by immunofluorescence staining for cleaved caspase-3. 
Results are from three independent experiments. Bars show mean and SEM. *P<0.05 by 
Student’s t-test.  Lower panel shows representative images.  Red cells are positive for 








Figure 7: Palbociclib treatment extends the survival of animals with medulloblastoma 
orthotopic xenografts  
 
 A) Palbociclib treatment (150mg/kg 5x per week) significantly increases survival of 
mice with D425Med orthotopic xenografts. *P=0.003 by Log-rank Test.  B) Palbociclib 
treatment (150mg/kg 5x per week) significantly increases survival of mice with DNp53 
hT AKT MYC orthotopic xenografts (*P=0.0322 by Log-rank Test). C) One 150 mg/kg 
dose of palbociclib deceased the percentage 4h prior to euthanasia of phospho-Rb 
positive cells in D425Med xenografts from 53% to 38% (*P=0.00025 by Student’s t-
test). Mice were euthanized 4h post dosing. C) IHC for phospho-Rb. Left column shows 
tumors from two separate animals treated with vehicle. Right column shows tumors from 
two separate animals treated with a single dose of 150mg/kg 4h prior to euthanasia. 














Figure 8: Medulloblastoma tumors and cell lines express GLS 
 
 A) Staining a 65-sample, subgrouped medulloblastoma tissue microarray (TMA) reveals 
that all subgroups present on the array have samples that express GLS.  B)  Human neural 
stem cells immortalized with SV40—not MYC—do not express GLS.  Stem cells 
transformed with MYC also express GLS.  C) The patient-derived medulloblastoma cell 




















Figure 9: Medulloblastoma cells expressing MYC are sensitive to Acivicin 
 
A, B) 10uM Acivicin treatment decreases the growth of D425Med and D283Med cells as 
measured by MTS assay.  C) 10uM Acivicin treatment significantly decreases the 
proliferation of human neural stem cells transformed by MYC or by DNp53, hTERT, 
AKT and MYC as measured by BrdU incorporation immunofluorescent staining.  Bars 
show mean and error bars indicate SEM.  (n= 4 to 2 biological replicates. *P<0.05 by 
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Student’s t-test). Lower panel shows representative images.  Red cells are positive for 
BrdU.  All cells counterstained with DAPI (blue).  D) 10uM Acivicin treatment 
significantly increased the percentage of cells expressing cleaved caspase-3, an indicator 
of apoptosis, as measured by immunofluorescence staining for cleaved caspase-3. Bars 
show mean and error bars indicate SEM. (n=2 to 4 biological replicates. *P<0.05 by 
Student’s t-test). Lower panel shows representative images. Red cells are positive for 


























Figure 10:  DON increases apoptosis in medulloblastoma cells expressing MYC  
 
A,B) Treatment with 10uM DON decreases the growth of D425Med and D283Med cells 
as measured by MTS assay. C) 10uMDON does not significantly decrease the 
proliferation of medulloblastoma cell lines as measured by BrdU incorporation. Bars 
show mean and error bars indicate SEM. (n=3 to 6 biological replicates. *P<0.05 by 
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Student’s t-test).  Lower panel shows representative images.  Red indicates cells positive 
for BrdU incorporation.  All cells counterstained with DAPI (blue).  D) 10uM DON 
treatment increases apoptosis in medulloblastoma cell lines as measured by 
immunofluorescence staining for cleaved caspase-3.  Bars show mean and error bars 
indicate SEM.  n=2 to 6 biological replicates.  *P<0.05 by Student’s t-test.  Lower panel 
shows representative images.  Red cells are positive for cleaved caspase-3.  All cells are 
























Figure 11: Normal human neural stem and progenitor cells are resistant to treatment with 
glutamine analogs  
A) The proliferation of normal human neural stem cells is not affected by 72h treatment 
with 10uM Acivicin or 10uM DON as measured by BrdU incorporation. The lower panel 
shows representative images.  Red cells are positive for BrdU and all cells were 
counterstained with DAPI (blue).  B) Treatment with 10uM Acivicin or 10uM DON did 
not significantly increase apoptosis in normal human neural stem cells as measured by 
cleaved caspase-3 immunofluorescence.  The lower panel shows representative images.  













Figure 12:  Acivicin treatment does not improve survival in mice with orthotopic 
medulloblastoma tumors 
A) 25mg/kg of Acivicin 4x a week did not significantly increase the survival of mice 
with orthotopic D425Med xenografts (*P=0.19 by Log-rank Test).  B) Increasing the 
dose of Acivicin to 75mg/kg 4x a week did not significantly increase survival of mice 
with D425Med orthotopic xenografts (*P=0.78 by Log-rank test).  C) 75m/kg 4x a week 
of Acivicin reduced the average volume of D283Med flank tumors.  D) Photograph of 












Figure 13:  DON therapy dramatically decreases tumor burden and improves survival in 
mice with medulloblastoma flank and orthotopic xenograft tumors.  
A) Once weekly 30mg/kg DON treatment significantly decreased the tumor burden of 
mice with D425Med flank xenografts. Each line in the graph is one individual tumor. 
Tumor volume was normalized to day zero.  B)  The average tumor volume in mice 
treated with DON decreased significantly, while tumors in animals treated with vehicle 
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increased in volume. Bars show mean and error bars SD.  n=19 control tumors n=20 
DON tumors (*P=0.001 by Student’s t-test.) C) Pictures of animals treated with 30mg/kg 
of DON 1x week.  The first dose of DON was administered on day 0. D) Treatment 
30mg/kg DON once weekly significantly increased the survival of mice with D425Med 
orthotopic xenografts (*P=0.0018 by Log-rank test).  Lower panel shows H&E stain of 
D425Med mouse brain tumor.  E) Once weekly 30mg/kg DON therapy increased the 
survival of mice with Med211 orthotopic xenografts (*P=0.0017 by Log-rank test).  



























Figure 14: The DON pro-drug JHU-083 increases survival in mice with D425Med 
orthotopic xenografts 
 
A) The chemical structures of JHU-083 and DON.  B) JHU-083 delivers DON to the 
plasma with a reduced Cmax. C) Treatment with 20mg/kg JHU-083 (DON equivalent 
dose) 3x week significantly improved the survival of mice with D425Med orthotopic 





Figure 15:  DON inhibits glutamine synthetase   
 
A) DON treatment did not reduce the total amount of glutamate in D425Med tumors 
(n=16 vehicle tumors, n=19 DON tumors). B) Tumors from animals treated with DON 
had lower levels of glutamine compared to tumors from vehicle treated animals. (n=16 
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vehicle tumors, n=19 DON tumors). C, D) Stable isotope metabolomics revealed that 
DON treated tumors had significantly lower amounts of the glutamate M+2 and 
glutamine M+2 isotoplogues than vehicle treated tumors (*P<0.00007, by Student’s t-
test). For C and D animals were labeled with 13C6-glucose (uniformly labeled glucose).  
Reduction in M+2 glutamate and glutamine suggests that DON is inhibiting of glutamine 
synthetase. (n=4 vehicle tumors, n=8 DON tumors) E) Simplified diagram of a single 
turn of the TCA cycle and the resulting isotopologues when uniformly 13C6-glucose is 
injected into the system. Glutamate dehydrogenase (GDH) is in blue.  Glutamine 


























Figure 16: DON inhibits asparagine synthetase 
A) D425Med tumors from animals treated with DON have less asparagine than tumors 
from vehicle treated animals. (n=16 vehicle tumors, n=19 DON tumors).   B) M+1 
asparagine levels in DON treated tumors are significantly lower than tumors from vehicle 




14N2-glutamine. (n=8 vehicle tumors, n=8 DON tumors).  C) Diagram 
showing how M+1 asparagine is synthesized by asparaginase (ASNS) adding a 14N from 
13C6-
14N2-glutamine to aspartate.  D) In 
13C6-glucose labeled tumors, those treated with 
DON had significantly lower levels of M+2 asparagine than vehicle treated tumors 
(*P=3.7x10-9 by Student’s t-test).   M+3 asparagine was not detected. (n=4 vehicle 
tumors n=8 DON tumors).  E) Simplified diagram of the TCA cycle when the system is 
injected with 13C6-glucose.  M+2 asparagine is synthesized by M+2 acetyl CoA entering 
the TCA cycle and being converted to M+2 oxaloacetate, then M+2 aspartate and finally 
M+2 asparagine by asparagine synthetase (ASNS, green).  M+3 asparagine is generated 
by the activity of pyruvate carboxylase (PC, blue) converting M+3 pyruvate to M+3 
oxaloacetate then M+3 aspartate then finally M+3 asparagine.  As no M+3 asparagine 
was detected (D), D425Med tumors likely have little pyruvate carboxylate activity. F) In 
13C6-glucose labeled tumors there was no difference in M+2 aspartate levels in tumors 
from DON vs vehicle treated mice (*P=0.40 by Student’s t-test) suggesting that DON 





















Figure 17:  DON and ASNase in combination are more effective at killing 
medulloblastoma cells than either drug alone.  
 
A) The growth of D425Med cells was slightly decreased by growth in 0.25 U/mL 
ASNase and partially decreased by growth in 4uM DON.  Growth was completely 
inhibited by the combination of 4uM DON and 0.25 U/mL.  B) The combination of 4uM 
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DON and 0.25 U/mL ASNase increased the percentage of cleaved caspase-3 positive 
cells more than either drug alone as measured by cleaved caspase-3 immunofluorescence.  
Bars show means and SEM.  (*P<0.05 by Student’s t-test.  n=3 biological replicates).  C, 
D) The combination of 4uM DON and 0.5 U/mL ASNase increased the percentage of 
cleaved caspase-3 positive cells more than either drug alone.  Bars show mean and SEM 
(*P<0.05 by Student’s t-test.  n=3 biological replicates). E) Representative images.  
D425Med cells were grown in 0.25 U/mL ASNase, while human neural stem cells 
transformed with MYC or DNp53 hT AKT MYC were grown in 0.5 U/mL ASNase.  























Figure 18:  Detailed diagram of the DiSCoVER method 
Schematic diagram showing the main analysis components and datasets that are part of 
the DisCoVER method. Note that there are only two mRNA datasets asthe CCLE and the 















Figure 19: Top scoring compounds from each of the signature vs drug sensitivity 
comaprisons.  
 
Top scoring compounds from each of the 3 signature vs. drug sensitivity comparisons. 
The y-axis is the Information coefficient (IC) and the x-axis the correlation coefficient. 
As can be seen in the Figure the CDK inhibitors are top hits in the 3 drug sensitivity 
datasets. The different scores in the x- and y-axis (correlation vs. information 
coefficients) are useful to appreciate how much of the relationship between the signature 
































3021 N Calvert St, Apt 3 
Baltimore MD 21218 
allison.hanaford@gmail.com 
(410) 502-5157 
400 N Broadway, Smith 4001N 






John Hopkins School of Medicine, Pathobiology Graduate Program, 




California State University Fullerton (CSUF), BS Biological Science, 
Minor in Music, Summa cum laude and University Honors, (June 2011) 
 
Awards and Honors  
2016 Oral Presentation Award, Pathobiology Program Retreat, Johns Hopkins 




Scholar-in-Training Award, American Brain Tumor Association and 




Award for Excellence in Translational Research, Pathology Young 




Award for Excellence in Translational Research, Pathology Young 









Award for Excellence in Translational Research, Pathology Young 




Award for Excellence in Translational Research, Pathology Young 

























President’s Scholar, full tuition scholarship, highest award given to 





Johns Hopkins School of Medicine, Baltimore MD 
Mentors: Dr. Charles Eberhart and Dr. Eric Raabe 
Project: Developing genetically accurate models and investigating 




Johns Hopkins School of Medicine, Baltimore MD 
Mentor: Dr. Sanjay Jain 
Project: Gene expression profiling of the Mycobacterium tuberculosis 





Johns Hopkins School of Medicine, Baltimore MD 
Mentor: Dr. Lee Martin 





The Jackson Laboratory Summer Student Program, Bar Harbor ME 
Mentor:  Leona Gagnon and Dr. Kenneth Johnson 




Hanaford AR, Archer TC, Price A, Kahlert UD, et al. DiSCoVERing innovative therapies  
for rare tumors: combining genetically accurate disease models with in silico 
analysis to identify novel therapeutic targets.  Clin Cancer Res. 2016 Aug 22 (15): 
3903-14. 
Asnaghi L, Tripathy A, Yang Q, Kaur H, Hanaford A, Yu W, and Eberhart CG.
 Targeting Notch signaling as a novel therapy for retinoblastoma. Onocotarget.
 2016 Oct 25 (43): 70028-44.  
Suwala AK.  Hanaford AR., Kahlert UD, Maciaczyk J. Clipping the wings of  
Glioblastoma: Modulation of WNT as a novel therapeutic strategy.  J Neuropathol 
Exp Neurol. 2016 May 75 (5): 388-96 
 
Martin, LJ, Samantha S, Hanaford A, Wong M.  The mitochondrial permeability  
transition pore regulates Parkinson's disease development in mutant α-synuclein  




Patents and Inventions  
# 61773189 “TARGETING GLUTAMINE METABOLISM IN BRAIN TUMORS.” 
Initial patent application filed March 6, 2013; updated patent filed 3/6/2014; submitted 
for US patent protection 9/6/2015 
 
Platform Presentations 
2016 CNS Anticancer Drug 
Discovery and Development 
Conference, Scottsdale, AZ 
Prodrugs of 6-diazo-5-oxo-norleucine 
improve oral absorption and brain 
penetration and demonstrate efficacy 





17th International Symposium 
on Pediatric Neuro-oncology, 
Liverpool, UK 
 
DiSCoVERing innovative therapies 
for medulloblastoma: combining 
genetically accurate disease models 






Basic and Translational 
Research Conference, San 
Diego, CA  
 
 
Pathway analysis of a human neural 
stem cell model of aggressive 
medulloblastoma reveals CDK 









Targeting Glutamine metabolism as a 






Basic and Translational 




A human neural stem cell model of 
medulloblastoma reveals glutamine 
metabolism as a potential therapeutic 
target 
 
Other Oral Presentations 
2016 Pathobiology Program Retreat, 
Johns Hopkins School of 
Medicine, Baltimore MD 
DiSCoVERing innovative therapies:  
Combining genetically accurate 
disease models of medulloblastoma 
with advanced in silico analysis to 




Brain Tumor Group Meeting, 
Johns Hopkins School of 
Medicine, Baltimore MD 
 
DiSCoVERing innovative therapies:  
Combining genetically accurate 
disease models of medulloblastoma 
with advanced in silico analysis to 
identify novel therapeutic targets 
103 
 
2015 Society for Neuro-oncology 
Neuro-Tumor Club Dinner, 
American Association for 
Cancer Research,  Annual 
Meeting 2015, Philadelphia PA 
Pathway analysis of a human neural 
stem cell model of aggressive 
medulloblastoma reveals CDK 





Society for Neuro-oncology 
Neuro-Tumor Club Dinner, 
American Association for 
Cancer Research Annual 
Meeting 2013, Washington DC 
 
A human neural stem cell model of 
medulloblastoma reveals glutamine 





Pathology Grand Rounds, 
Johns Hopkins School of 
Medicine, Baltimore MD 
 
 
A human neural stem cell model of 
medulloblastoma reveals glutamine 






Monthly Seminar, Johns 
Hopkins School of Medicine, 
Baltimore MD 
 
Glutamine metabolism as a potential 




2016 American Association for 
Cancer Research Annual 
Meeting 2016, New Orleans, 
LA 
DiSCoVERing innovative therapies 
for rare tumors: combining genetically 
accurate disease models with in silico 






Investigator’s Day, Johns 
Hopkins School of Medicine, 
Baltimore MD 
 
DiSCoVERing innovative therapies 
for rare tumors: combining genetically 
accurate disease models with in silico 





Pathobiology Program Retreat, 
Johns Hopkins School of 
Medicine, Baltimore MD 
 
Pathway analysis of a human neural 
stem cell model of medulloblastoma 






Investigator’s Day, Johns 
Hopkins School of Medicine, 
Baltimore MD  
 
Pathway analysis of a human neural 
stem cell model of aggressive 
medulloblastoma reveals CDK 




2015 American Association for 
Cancer Research Annual 
Meeting 2015, Philadelphia, 
PA 
Glutamine metabolic inhibitors 
suppress growth and tumorigenicity in 






Investigator’s Day, Johns 
Hopkins School of Medicine  
 
Targeting Glutamine metabolism as a 





American Association for 
Cancer Research Annual 
Meeting 2014, San Diego, CA 
 
Targeting Glutamine metabolism as a 





Pathobiology Program Retreat, 
Johns Hopkins School of 
Medicine, Baltimore MD 
 
Targeting MYC-driven 






Investigator’s Day, Johns 









American Association for 
Cancer Research Annual 
Meeting 2013, Washington DC 
 
Targeting MYC-driven 





2012-2016 Teaching  Assistant Introduction to Biomedical Sciences, Bloomberg 
School of Public Health 
2012, 2014 Teaching Assistant Pathology: Basic Mechanisms, Johns Hopkins 
School of Medicine 
 
Leadership Experience  
2013-2014 Chief Graduate Student Pathobiology Program, Johns Hopkins 





Baltimore Alumnae Chapter, Sigma Alpha 
Iota International Music Fraternity, 
Baltimore MD  
2013-2014 Vice President, Ritual Baltimore Alumnae Chapter, Sigma Alpha 







Lambda Chi Chapter, Sigma Alpha Iota 







American Association of Cancer Research 
Phi Kappa Phi 
National Society of Collegiate Scholars 
Golden Key International Honors Society 
 
